UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549


FORM 10-Q


 

(Mark one)

☒         QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended DecemberMarch 31, 20212022

 

or

 

☐         TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from                         to                           .

 

Commission File Number: 000-24248


logo.jpg

 

GENASYS INC.

(Exact name of registrant as specified in its charter)


Delaware

87-0361799

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification Number)

  

16262 West Bernardo Drive, San Diego,

California

92127

(Address of principal executive offices)

(Zip Code)

 

(858) 676-1112

(Registrants telephone number, including area code)


 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which securities are registered

Common stock, $0.00001 par value per share

GNSS

NASDAQ Capital Market

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.   ☒   Yes     ☐  No

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    ☒  Yes    ☐  No

 

 

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

    

Non-accelerated filer

Smaller reporting company

    

Emerging growth company

  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    ☐  Yes  ☒    No

 

The number of shares of Common Stock, $0.00001 par value, outstanding on February 3,May 5, 2022 was 36,407,072.

36,578,085.



 

 

 

PART I. FINANCIAL INFORMATION

 

Item 1.         Financial Statements

Genasys Inc.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except par value and share amounts)

 

 

December 31,

     

March 31,

    
 

2021

 

September 30,

  

2022

 

September 30,

 
 

(Unaudited)

  

2021

  

(Unaudited)

  

2021

 

ASSETS

  

Current assets:

  

Cash and cash equivalents

 $10,136  $13,167  $8,977  $13,167 

Short-term marketable securities

 3,938  5,686  5,204  5,686 

Restricted cash

 273  279  267  279 

Accounts receivable, net

 6,787  7,682  5,550  7,682 

Inventories, net

 9,142  6,416  9,642  6,416 

Prepaid expenses and other

  1,223   2,255   1,479   2,255 

Total current assets

 31,499  35,485  31,119  35,485 
  

Long-term marketable securities

 3,381  1,875  2,264  1,875 

Long-term restricted cash

 1,083  1,082  1,096  1,082 

Deferred tax assets, net

 8,330  8,039  8,375  8,039 

Property and equipment, net

 1,821  1,755  1,726  1,755 

Goodwill

 23,787  23,834  23,830  23,834 

Intangible assets, net

 12,251  12,804  11,735  12,804 

Operating lease right of use assets

 4,689  4,862  4,508  4,862 

Other assets

  439   392   405   392 

Total assets

 $87,280  $90,128  $85,058  $90,128 
  

LIABILITIES AND STOCKHOLDERS' EQUITY

  

Current liabilities:

  

Accounts payable

 $2,259  $2,160  $2,956  $2,160 

Accrued liabilities

 12,611  14,111  10,161  14,111 

Notes payable

 290  296  267  296 

Operating lease liabilities, current portion

  906   899   896   899 

Total current liabilities

 16,066  17,466  14,280  17,466 
  

Other liabilities, noncurrent

 995  995  1,030  995 

Operating lease liabilities, noncurrent

  5,488   5,709   5,276   5,709 

Total liabilities

 22,549  24,170  20,586  24,170 
  

Stockholders' equity:

  

Preferred stock, $0.00001 par value; 5,000,000 shares authorized; none issued and outstanding

 0  0  0  0 

Common stock, $0.00001 par value; 100,000,000 shares authorized; 36,371,529 and 36,403,833 shares issued and outstanding, respectively

 0  0 

Common stock, $0.00001 par value; 100,000,000 shares authorized; 36,528,085 and 36,403,833 shares issued and outstanding, respectively

 0  0 

Additional paid-in capital

 107,273  107,110  107,507  107,110 

Accumulated deficit

 (42,459) (41,154) (42,951) (41,154)

Accumulated other comprehensive income (loss)

  (83)  2   (84)  2 

Total stockholders' equity

  64,731   65,958   64,472   65,958 

Total liabilities and stockholders' equity

 $87,280  $90,128  $85,058  $90,128 

 

See accompanying notes

 

1

 

 

Genasys Inc.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(in thousands, except per share and share amounts)

(Unaudited)

 

 

Three months ended

  

Three months ended

 

Six months ended

 
 

December 31,

  

March 31,

 

March 31,

 
 

2021

  

2020

  

2022

  

2021

  

2022

  

2021

 

Revenues:

  

Product sales

 $9,570  $6,950  $11,854  $10,131  $21,424  $17,081 

Contract and other

  1,107   1,078   1,314   1,170   2,421   2,248 

Total revenues

 10,677  8,028  13,168  11,301  23,845  19,329 

Cost of revenues

  5,783   4,324   6,208   6,047   11,743   10,350 
  

Gross profit

  4,894   3,704   6,960   5,254   12,102   8,979 
  

Operating expenses

  

Selling, general and administrative

 5,134  3,331  5,594  3,824  10,631  7,155 

Research and development

  1,369   1,066   1,893   877   3,607   1,964 

Total operating expenses

 6,503  4,397  7,487  4,701  14,238  9,119 
  

Loss from operations

 (1,609) (693)

(Loss) income from operations

 (527) 553  (2,136) (140)
  

Other income, net

  13   69 

Other (loss) income, net

  (10)  (8)  3   61 
  

Loss before income taxes

 (1,596) (624)

Income tax benefit

  (291)  (5)

Net loss

 $(1,305) $(619)

(Loss) income before income taxes

 (537) 545  (2,133) (79)

Income tax (benefit) expense

  (45)  283   (336)  278 

Net (loss) income

 $(492) $262  $(1,797) $(357)
  
  

Net loss per common share - basic and diluted

 $(0.04) $(0.02)

Net (loss) income per common share - basic

 $(0.01) $0.01  $(0.05) $(0.01)

Diluted

 $(0.01) $0.01  $(0.05) $(0.01)

Weighted average common shares outstanding:

  

Basic and diluted

  36,456,187   33,573,755 

Basic

  36,353,321   33,683,240   36,405,321   33,629,479 

Diluted

  36,353,321   34,779,266   36,405,321   33,629,479 

 

See accompanying notes

 

2

 

Genasys Inc.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS(LOSS) INCOME

(in thousands)

(Unaudited)

 

  

Three months ended

 
  

December 31,

 
  

2021

  

2020

 

Net loss

 $(1,305) $(619)

Other comprehensive income (loss)

        

Unrealized loss on marketable securities

  (10)  (3)

Unrealized foreign currency (loss) gain

  (75)  472 

Comprehensive loss

 $(1,390) $(150)
  

Three months ended

  

Six months ended

 
  

March 31,

  

March 31,

 
  

2022

  

2021

  

2022

  

2021

 

Net (loss) income

 $(492) $262  $(1,797) $(357)

Other comprehensive (loss) income

                

Unrealized loss on marketable securities

  (59)  (3)  (69)  (6)

Unrealized foreign currency gain (loss)

  58   (75)  (17)  397 

Comprehensive (loss) income

 $(493) $184  $(1,883) $34 

 

3

 

Genasys Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(Unaudited)

 

 

Three Months Ended

  

Six Months Ended

 

 

December 31,

  

March 31,

 
 

2021

  

2020

  

2022

  

2021

 

Operating Activities:

  

Net loss

 $(1,305) $(619) $(1,797) $(357)
  

Adjustments to reconcile net income to net cash provided by operating activities:

  

Depreciation and amortization

 639  281  1,282  552 

Amortization of debt issuance costs

 5  0  10  2 

Warranty provision

 4  15  16  37 

Inventory obsolescence

 26  100  64  196 

Stock-based compensation

 558  182  1,295  510 

Realized loss on foreign currency forward contract

 0  (76) 0  (76)

Deferred income taxes

 (291) (5) (336) 278 

Amortization of operating lease right of use asset

 178  170  360  343 

Accretion of acquisition holdback liability

 12  0  24  22 
  

Changes in operating assets and liabilities:

  

Accounts receivable, net

 889  2,300  2,123  (14)

Inventories, net

 (2,752) (1,114) (3,291) (698)

Prepaid expenses and other

 979  120  750  (253)

Accounts payable

 99  232  805  1,184 

Accrued and other liabilities

  (1,743)  (314)  (4,412)  (1,363)

Net cash (used in) provided by operating activities

  (2,702)  1,272   (3,107)  363 
  

Investing Activities:

  

Purchases of marketable securities

 (2,655) (1,793) (3,656) (2,799)

Proceeds from maturities of marketable securities

 2,886  1,925  3,681  2,939 

Cash paid for acquisitions net of cash acquired

 0  (4,367) 0  (4,367)

Capital expenditures

  (159)  (29)  (171)  (148)

Net cash provided by (used in) investing activities

  72   (4,264)

Net cash used in investing activities

  (146)  (4,375)
  

Financing Activities:

  

Proceeds from exercise of stock options

 46  54  170  170 

Repurchase of common stock

  (441)  0  (998) 0 

Net cash (used in) provided by financing activities

  (395)  54 

Shares retained for payment of taxes in connection with settlement of restricted stock units

 (70) (141)

Payments on promissory notes

 (17) (18)

Cash paid for debt issuance costs

  0   (38)

Net cash used in financing activities

  (915)  (27)

Effect of foreign exchange rate on cash

  (11)  1   (20)  (30)

Net decrease in cash, cash equivalents, and restricted cash

 (3,036) (2,937) (4,188) (4,069)

Cash, cash equivalents and restricted cash, beginning of period

  14,528   23,996   14,528   23,996 

Cash, cash equivalents and restricted cash, end of period

 $11,492  $21,059  $10,340  $19,927 
  

Reconciliation of cash, cash equivalents and restricted cash to the consolidated balance sheets:

  

Cash and cash equivalents

 $10,136  $19,584  $8,977  $18,455 

Restricted cash, current portion

 273  295  267  282 

Long-term restricted cash

  1,083   1,180   1,096   1,190 

Total cash, cash equivalents and restricted cash shown in the consolidated statement of cash flows

 $11,492  $21,059  $10,340  $19,927 

 

See accompanying notes

 

4

 

Genasys Inc.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (continued)

(in thousands)

(Unaudited)

 

 

Three Months Ended

  

Six Months Ended

 
 

December 31,

  

March 31,

 
 

2021

  

2020

  

2022

  

2021

 

Noncash investing and financing activities:

  

Change in unrealized loss on marketable securities

 $(10) $(3) $(69) $(6)

Obligation to issue common stock in connection with the Amika Mobile asset purchase

 $(832) $(3,431) $(832) $(3,431)

Initial measurement of operating lease right of use assets

 $7  $248  $7  $(259)

Initial measurement of operating lease liabilities

 $7  $248  $7  $(259)
  

Business combinations accounted for as a purchase

  

Fair value of net assets acquired

 $0  $8,411  $0  $613 

 

5

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

 

 

1. OPERATIONS

 

Genasys Inc. (the “Company”) is a global provider of critical communications hardware and software solutionssystems designed to alert, inform, and protect. The Company's unified platform receives information from a wide variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. The Company uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations.

 

 

2. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

 

General

 

The Company’s unaudited interim condensed consolidated financial statements included herein have been prepared in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X and the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations. In management’s opinion, the accompanying financial statements reflect adjustments necessary to present fairly the financial position, results of operations, and cash flows for those periods indicated, and contain adequate disclosure to make the information presented not misleading. Adjustments included herein are of a normal, recurring nature unless otherwise disclosed in the footnotes. The condensed consolidated financial statements and notes thereto should be read in conjunction with the Company’s audited financial statements and notes thereto for the year ended September 30, 2021, included in the Company’s Annual Report on Form 10-K, as filed with the SEC on November 23, 2021. The accompanying condensed consolidated balance sheet as of September 30, 2021 has been derived from the audited consolidated balance sheet as of September 30, 2021 contained in the above referenced Form 10-K. Results of operations for interim periods are not necessarily indicative of the results of operations for a full year.

 

Principles of consolidation

 

The Company has eight wholly owned subsidiaries, Genasys II Spain, S.A.U. (“Genasys Spain”), Genasys Communications Canada ULC (“Genasys Canada”), Genasys Singapore PTE Ltd, Genasys Puerto Rico, LLC, Zonehaven LLC, and Genasys Inc. (branch) in the United Arab Emirates and two currently inactive subsidiaries, Genasys America de CV and LRAD International Corporation. The consolidated financial statements include the accounts of these subsidiaries after elimination of intercompany transactions and accounts.

 

Cash, cash equivalents and restricted cash

 

The Company considers all highly liquid investments with an original maturity of three months or less, when purchased, to be cash equivalents. As of DecemberMarch 31, 2021,2022, the amount of cash and cash equivalents was $10,136.$8,977. As of September 30, 2021, the amount of cash and cash equivalents was $13,167.

 

The Company considers any amounts pledged as collateral or otherwise restricted for use in current operations to be restricted cash. In addition, the Company excludes from cash and cash equivalents cash required to fund specific future contractual obligations related to business combinations. Restricted cash is classified as a current asset unless amounts are not expected to be released and available for use in operations within one year. As of DecemberMarch 31, 2021,2022, the current portion of restricted cash was $273$267, and the noncurrent portion was $1,083.$1,096. As of September 30, 2021, the current portion of restricted cash was $279, and the noncurrent portion was $1,082.$1,082.

 

Reclassifications

 

Where necessary, thecertain prior year’s information has been reclassified to conform to the current year presentation.

 

 

3. RECENT ACCOUNTING PRONOUNCEMENTS

 

New pronouncements pending adoption

 

In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2016-13, Measurement of Credit Losses on Financial Instruments, which supersedes current guidance by requiring recognition of credit losses when it is probable that a loss has been incurred. The new standard requires the establishment of an allowance for estimated credit losses on financial assets including trade and other receivables at each reporting date. The new standard will result in earlier recognition of allowances for losses on trade and other receivables and other contractual rights to receive cash. In November 2019, the FASB issued ASU No. 2019-10, Financial Instruments Credit Losses (ASC 326), Derivatives and Hedging (ASC 815) and Leases (ASC 842), which extends the effective date of ASC 326 for certain companies until fiscal years beginning after December 15, 2022. The new standard will be effective for the Company in the first quarter of fiscal year beginning October 1, 2023, and early adoption is permitted. The Company has not completed its review of the impact of this standard on its consolidated financial statements. However, based on the Company’s history of immaterial credit losses from trade receivables, the Company does not expect that the adoption of this standard will have a material effect on the Company’s consolidated financial statements.

 

6

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

In March 2020, the FASB issued ASU No. 2020-04, Reference Rate Reform (ASC 848), Facilitation of the Effects of Reference Rate Reform on Financial Reporting. ASU No. 2020-04 provides optional guidance, expedients and exceptions for a limited period of time to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting. The amendments in this update apply to all entities, subject to meeting the criteria, which participate in contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. ASU No. 2020-04 was subsequently amended by ASU No. 2021-01, Reference Rate Reform (ASC 848), Scope, which refines the scope of ASC 848 and permits optional expedients and exceptions when accounting for derivative contracts and certain hedging relationships. The amendments of these updates are available to all entities as of March 12, 2020 through December 31, 2022. The Company intends to adopt this standard when LIBOR is discontinued. The Company does not expect that the adoption of this standard will have a material effect on the Company’s consolidated financial statements.

 

 

4.

REVENUE RECOGNITION

The Company adopted ASU 2014-09, Revenue from Contracts with Customers (ASC 606), and its amendments on October 1, 2018. The Company adopted ASC 606 using the full retrospective approach.REVENUE RECOGNITON

 

ASC 606 outlines a new, single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most revenue recognition guidance, including industry-specific guidance. This new revenue recognition model provides a five-step analysis in determining when and how revenue is recognized:

 

 

1.

Identify the contract(s) with customers

 

2.

Identify the performance obligations

 

3.

Determine the transaction price

 

4.

Allocate the transaction price to the performance obligations

 

5.

Recognize revenue when the performance obligations have been satisfied

 

ASC 606 requires revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration a company expects to receive in exchange for those goods or services.

 

The Company derives its revenue from the sale of products to customers, contracts, software license fees, other services and freight. The Company sells its products through its direct sales force and through authorized resellers and system integrators. The Company recognizes revenue for goods including software when all the significant risks and rewards have been transferred to the customer, no continuing managerial involvement usually associated with ownership of the goods is retained, no effective control over the goods sold is retained, the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transactions will flow to the Company and the costs incurred or to be incurred in respect of the transaction can be measured reliably. Software license revenue, maintenance and/or software development service fees may be bundled in one arrangement or may be sold separately.

 

Product revenue

 

Product revenue is recognized as a distinct single performance obligation when products are tendered to a carrier for delivery, which represents the point in time that the Company’s customer obtains control of the products. A smaller portion of product revenue is recognized when the customer receives delivery of the products. A portion of products are sold through resellers and system integrators based on firm commitments from an end user, and as a result, resellers and system integrators carry little or no inventory. The Company’s customers do not have a right to return product unless the product is found defective and therefore the Company’s estimate for returns has historically been insignificant

 

Perpetual licensed software

 

The sale and/or license of software products is deemed to have occurred when a customer either has taken possession of, or has the ability to take immediate possession of the software and the software key. Perpetual software licenses can include one-year maintenance and support services. In addition, the Company sells maintenance services on a stand-alone basis and is therefore capable of determining their fair value. On this basis, the amount of the embedded maintenance is separated from the fee for the perpetual license and is recognized on a straight-line basis over the period to which the maintenance relates.

 

7

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

Time-based licensed software

 

The time-based license agreements include the use of a software license for a fixed term, generally one-year, and maintenance and support services during the same period. The Company does not sell time-based licenses without maintenance and support services and therefore revenues for the entire arrangements are recognized on a straight-line basis over the term.

 

7

Genasys Inc.
Notes to the Condensed Consolidated Financial Statements
(in thousands, except per share and share amounts)
(Unaudited)

Warranty, maintenance and services

 

The Company offers extended warranty, maintenance and other services. Extended warranty and maintenance contracts are offered with terms ranging from one to several years, which provide repair and maintenance services after expiration of the original one-year warranty term. Revenues from separately priced extended warranty and maintenance contracts are recognized based on time elapsed over the service period and classified as contract and other revenues. Revenue from other services such as training or installation is recognized when the service is completed.

 

Multiple element arrangements

 

The Company has entered into a number of multiple element arrangements, such as the sale of a product or perpetual licenses that may include maintenance and support (included in price of perpetual licenses) and time-based licenses (that include embedded maintenance and support, both of which may be sold with software development services, training, and other product sales). In some cases, the Company delivers software development services bundled with the sale of the software. In multiple element arrangements, the Company uses either the stand-alone selling price or an expected cost plus margin approach to determine the fair value of each element within the arrangement, including software and software-related services such as maintenance and support. In general, elements in such arrangements are also sold on a stand-alone basis and stand-alone selling prices are available.

 

Revenue is allocated to each deliverable based on the fair value of each individual element and is recognized when the revenue recognition criteria described above are met, except for time-based licenses which are not unbundled. When software development services are performed and are considered essential to the functionality of the software, the Company recognizes revenue from the software development services on a stage of completion basis, and the revenue from the software when the related development services have been completed.

 

The Company disaggregates revenue by reporting segment (Hardware and Software) and geographically to depict the nature of revenue in a manner consistent with its business operations and to be consistent with other communications and public filings. Refer to Note 18, Segment Information and Note 19, Major Customers, Suppliers and Related Information for additional details of revenues by reporting segment and disaggregation of revenue.

 

Contract assets and liabilities

 

The Company enters into contracts to sell products and provide services and recognizes contract assets and liabilities that arise from these transactions. The Company recognizes revenue and corresponding accounts receivable according to ASC 606 and, at times, recognizes revenue in advance of the time when contracts give the Company the right to invoice a customer. Sales commissions are considered incremental and recoverable costs of obtaining a contract with a customer. Subscription related commission costs are deferred and then amortized on a straight-line basis over the period of benefit. The Company may also receive consideration, per terms of a contract, from customers prior to transferring goods to the customer. The Company records customer deposits as a contract liability. Additionally, the Company may receive payments, most typically for service and warranty contracts, at the onset of the contract and before the services have been performed. In such instances, a deferred revenue liability is recorded. The Company recognizes these contract liabilities as revenue after all revenue recognition criteria are met. The table below reflects the balances of contract liabilities as of DecemberMarch 31, 20212022 and September 30, 2021, including the change between the periods. There were 0 contract assets as of DecemberMarch 31, 20212022 and September 30, 2021. The current portion of contract liabilities and the non-current portion are included in “Accrued liabilities” and “Other liabilities, noncurrent”, respectively, on the accompanying condensed consolidated balance sheets. Refer to Note 10, Accrued and Other Liabilities for additional details.

 

8

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

The Company’s contract liabilities were as follows:

 

 

Customer

deposits

 

Deferred

revenue

 

Total contract

liabilities

  

Customer

deposits

 

Deferred

revenue

 

Total contract

liabilities

 

Balance as of September 30, 2021

 $8,701  $1,428  $10,129  $8,701  $1,428  $10,129 

New performance obligations

 2,627  410  3,037  4,298  801  5,099 

Recognition of revenue as a result of satisfying performance obligations

 (2,754) (452) (3,206) (7,259) (941) (8,200)

Effect of exchange rate on deferred revenue

  0  2  2   0  1  1 

Balance as of December 31, 2021

 $8,574  $1,388  $9,962 

Balance as of March 31, 2022

 $5,740  $1,289  $7,029 

Less: non-current portion

  0  (296) (296)  0  (307) (307)

Current portion as of December 31, 2021

 $8,574  $1,092  $9,666 

Current portion as of March 31, 2022

 $5,740  $982  $6,722 

 

8

Genasys Inc.
Notes to the Condensed Consolidated Financial Statements
(in thousands, except per share and share amounts)
(Unaudited)

Remaining performance obligations

 

Remaining performance obligations related to ASC 606 represent the aggregate transaction price allocated to performance obligations under an original contract with a term greater than one year, which are fully or partially unsatisfied at the end of the period.

 

As of DecemberMarch 31, 2022, 31,2021,the aggregate amount of the transaction price allocated to remaining performance obligations was approximately $9,962.$7,029. The Company expects to recognize revenue on approximately $9,666$6,722 or 97%96% of the remaining performance obligations over the next 12 months, and the remainder is expected to be recognized thereafter.

 

Practical expedients 

 

In cases where the Company is responsible for shipping after the customer has obtained control of the goods, the Company has elected to treat these activities as fulfillment activities rather than as a separate performance obligation. Additionally, the Company has elected to capitalize the cost to obtain a contract only if the period of amortization would be longer than one year. The Company only gives consideration to whether a customer agreement has a financing component if the period of time between transfer of goods and services and customer payment is greater than one year. The Company also utilizes the “as invoiced” practical expedient in certain cases where performance obligations are satisfied over time and the invoiced amount corresponds directly with the value the Company is providing to the customer.

 

 

5. FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS

 

The Company’s financial instruments consist principally of cash equivalents, short and long-term marketable securities, accounts receivable, and accounts payable. The fair value of a financial instrument is the amount that would be received in an asset sale or paid to transfer a liability in an orderly transaction between unaffiliated market participants. Assets and liabilities measured at fair value are categorized based on whether or not the inputs are observable in the market and the degree that the inputs are observable. The categorization of financial instruments within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement. The hierarchy is prioritized into three levels (with Level 3 being the lowest) defined as follows:

 

 

Level 1:

Inputs are based on quoted market prices for identical assets or liabilities in active markets at the measurement date.

 

Level 2:

Inputs include quoted prices for similar assets or liabilities in active markets and/or quoted prices for identical or similar assets or liabilities in markets that are not active near the measurement date.

 

Level 3:

Inputs include management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. The inputs are unobservable in the market and significant to the instrument’s valuation.

 

The fair value of the Company’s cash equivalents and marketable securities were determined based on Level 1 and Level 2 inputs. The valuation techniques used to measure the fair value of the “Level 2” instruments were based on quoted market prices or model-driven valuations using significant inputs derived from or corroborated by observable market data. The Company believes that the recorded values of its other financial instruments approximate their current fair values because of their nature and respective relatively short maturity dates or durations. The Company did not have any marketable securities in the Level 3 category as of DecemberMarch 31, 20212022 or September 30, 2021. There have been no changes in Level 1, Level 2, and Level 3 and no changes in valuation techniques for financial instruments measured at fair value on a recurring basis for the periods ended DecemberMarch 31, 20212022 and September 30, 2021.

 

9

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

Instruments measured at fair value on a recurring basis

 

Cash equivalents and marketable securities: The following tables present the Company’s cash equivalents and marketable securities’ costs, gross unrealized gains and losses, and fair value by major security type recorded as cash equivalents or short-term or long-term marketable securities as of DecemberMarch 31, 20212022 and September 30, 2021. Unrealized gains and losses from the remeasurement of marketable securities are recorded in accumulated other comprehensive income (loss) until recognized in earnings upon the sale or maturity of the security.

 

9

Genasys Inc.
Notes to the Condensed Consolidated Financial Statements
(in thousands, except per share and share amounts)
(Unaudited)
  

March 31, 2022

 
  

Cost Basis

  

Unrealized
Gain (Loss)

  

Fair Value

  

Cash
Equivalents

  

Short-term
Securities

  

Long-term
Securities

 

Level 1:

                        

Money market funds

 $988  $0  $988  $988  $-  $- 
                         

Level 2:

                        

Certificates of deposit

  1,244   0   1,244   0   942   302 

Municipal securities

  5,370   (48)  5,322   0   4,126   1,196 

Corporate bonds

  923   (21)  902   0   136   766 

Subtotal

  7,537   (69)  7,468   0   5,204   2,264 
                         

Total

 $8,525  $(69) $8,456  $988  $5,204  $2,264 

 

  

December 31, 2021

 
  

Cost Basis

  

Unrealized

Gain (Loss)

  

Fair Value

  

Cash

Equivalents

  

Short-term

Securities

  

Long-term

Securities

 

Level 1:

                        

Money Market Funds

 $1,181  $0  $1,181  $1,181  $-  $- 
                         

Level 2:

                        

Certificates of deposit

  1,493   0   1,493   0   693   800 

Municipal securities

  4,907   (5)  4,902   0   3,106   1,796 

Corporate bonds

  929   (5)  924   0   139   785 

Subtotal

  7,329   (10)  7,319   0   3,938   3,381 
                         

Total

 $8,510  $(10) $8,500  $1,181  $3,938  $3,381 

 

September 30, 2021

  

September 30, 2021

 
 

Cost Basis

  

Unrealized

Gain (Loss)

  

Fair Value

  

Cash

Equivalents

  

Short-term

Securities

  

Long-term

Securities

  

Cost Basis

  

Unrealized
Gain (Loss)

  

Fair Value

  

Cash
Equivalents

  

Short-term
Securities

  

Long-term
Securities

 

Level 1:

  

Money Market Funds

 $932  $0  $932  $932  $-  $- 

Money market funds

 $932  $0  $932  $932  $-  $- 
  

Level 2:

  

Certificates of deposit

 1,494  0  1,494  0  694  800  1,494  0  1,494  0  694  800 

Municipal securities

 5,139  (1) 5,138  0  4,205  933  5,139  (1) 5,138  0  4,205  933 

Corporate bonds

  928   1   929   0   787   142   928   1   929   0   787   142 

Subtotal

  7,561   0   7,561   0   5,686   1,875   7,561   0   7,561   0   5,686   1,875 
                          

Total

 $8,493  $0  $8,493  $932  $5,686  $1,875  $8,493  $0  $8,493  $932  $5,686  $1,875 

 

Instruments measured at fair value on a non-recurring basis

 

Nonfinancial assets: Nonfinancial assets such as goodwill, other intangible assets, long-lived assets held and used, and right-of-use (“ROU”) assets (“ROU assets”) are measured at fair value when there is an indicator of impairment and recorded at fair value only when impairment is recognized or for a business combination. 

 

Goodwill and intangible assets are recognized at fair value during the period in which an acquisition is completed, from updated estimates during the measurement period, or when they are considered to be impaired. These non-recurring fair value measurements, primarily for intangible assets acquired, were based on Level 3 inputs. The Company estimates the fair value of these long-lived assets on a non-recurring basis based on a market valuation approach, engaging independent valuation experts to assist in the determination of fair value.

 

The following table presents nonfinancial assets that were subject to fair value measurement during the threesix months ended DecemberMarch 31, 2021.2022. Certain intangible assets, operating lease ROU assets and goodwill are subject to foreign currency translation adjustments. There were no business combinations or indicators of impairment for the threesix months ended DecemberMarch 31, 2021.2022.

 

  

Carrying

Value

  

Level 1

  

Level 2

  

Level 3

  

Gain/ (Loss)

 

Operating lease ROU asset

 $7  $0  $0   7  $0 

 

10

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

Holdback Liability: In connection with the Amika Mobile asset purchase, the Company recorded a holdback liability related to potential future adjustments to assets and liabilities, misrepresentations and indemnifications against third-party claims. Adjustments of up to CAD$1,000 (USD$787799) will be deducted from the asset purchase holdback liability for up to three years from the closing date. The holdback liability was recorded at the present value which was the fair value at the acquisition date. The Company engaged independent valuation experts to assist in determining the present value of the holdback liability. The expected future payment was discounted using a rate representative of the Company’s payment risk and credit rating. Accretion is recorded in each subsequent reporting period based on the discount factor used to arrive at the original fair value. This change in fair value is recorded in the accompanying condensed consolidated statement of operations. The changes in the carrying amount of the holdback liability is as follows:

 

Balance as of September 30, 2021

 $687 

Accretion

  11 

Currency translation

  1 

Balance as of December 31, 2021

 $699 

Balance as of September 30, 2021

 $687 

Accretion

  24 

Currency translation

  12 

Balance as of March 31, 2022

 $723 

 

 

6. INVENTORIES, NET

 

Inventories, net consisted of the following:

 

  

December 31,

  

September 30,

 
  

2021

  

2021

 

Raw materials

 $8,401  $5,449 

Finished goods

  893   842 

Work in process

  552   877 

Inventories, gross

  9,846   7,168 

Reserve for obsolescence

  (704)  (752)

Inventories, net

 $9,142  $6,416 

  

March 31,

  

September 30,

 
  

2022

  

2021

 

Raw materials

 $8,280  $5,449 

Finished goods

  723   842 

Work in process

  1,381   877 

Inventories, gross

  10,384   7,168 

Reserve for obsolescence

  (742)  (752)

Inventories, net

 $9,642  $6,416 

 

 

7. PROPERTY AND EQUIPMENT, NET

 

Property and equipment, net consisted of the following:

 

 

December 31,

 

September 30,

  

March 31,

 

September 30,

 
 

2021

  

2021

  

2022

  

2021

 

Office furniture and equipment

 $1,309  $1,261  $1,355  $1,261 

Machinery and equipment

 1,380  1,270  1,380  1,270 

Leasehold improvements

  2,154   2,154   2,173   2,154 

Property and equipment, gross

 4,843  4,685  4,908  4,685 

Accumulated depreciation

  (3,022)  (2,930)  (3,182)  (2,930)

Property and equipment, net

 $1,821  $1,755  $1,726  $1,755 

 

  

Three Months Ended

 
  

December 31,

 
  

2021

  

2020

 

Depreciation expense

 $96  $99 

Depreciation expense was $102 and $101 for the three months ended March 31, 2022 and 2021, respectively, and $199 and $200 for the six months ended March 31, 2022 and 2021, respectively.

 

 

8. GOODWILL AND INTANGIBLE ASSETS

 

Goodwill is attributable to the acquisitions of Genasys Spain and Zonehaven, and the Amika Mobile asset purchase and is due to combining the integrated emergency critical communications, mass messaging solutions and software development capabilities with existing hardware products for enhanced offerings and the skill level of the acquired workforces. The Company periodically reviews goodwill for impairment in accordance with relevant accounting standards.

 

There were no additions to goodwill during the threesix months ended DecemberMarch 31, 2021.2022. During the year ended September 30, 2021, the Company added a total of $21,128 in goodwill related to the Zonehaven acquisition and the Amika Mobile asset purchase. As of DecemberMarch 31, 20212022 and September 30, 2021, goodwill was $23,787$23,830 and $23,834, respectively. There were 0 impairments to goodwill during the threesix months ended DecemberMarch 31, 2021.2022.

 

11

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

The changes in the carrying amount of goodwill by segment for the threesix months ended DecemberMarch 31, 2021,2022, were as follows:

 

 

Hardware

  

Software

  

Total

  

Hardware

  

Software

  

Total

 

Balance as of September 30, 2021

 $0  $23,834  $23,834  $0  $23,834  $23,834 

Currency translation

  0   (47)  (47)  0   (4)  (4)

Balance as of December 31, 2021

 $0  $23,787  $23,787 

Balance as of March 31, 2022

 $0  $23,830  $23,830 

 

Intangible assets and goodwill related to Genasys Spain are translated from Euros to U.S. dollars at the balance sheet date. The net impact of foreign currency exchange differences arising during the period related to goodwill and intangible assets was a decrease of $65.$125. Intangible assets and goodwill related to Amika Mobile are translated from Canadian dollars to U.S. dollars at the balance sheet date. The net impact of foreign currency exchange differences arising during the period related to goodwill and intangible assets was an increase of $8.$135.

 

The changes in the carrying amount of intangible assets by segment for the threesix months ended DecemberMarch 31, 2021,2022, were as follows:

 

 

Hardware

  

Software

  

Total

  

Hardware

  

Software

  

Total

 

Balance as of September 30, 2021

 $25  $12,779  $12,804  $25  $12,779  $12,804 

Amortization

 (1) (542) (543) (2) (1,081) (1,083)

Currency translation

  0   (10)  (10)  0   14   14 

Balance as of December 31, 2021

 $24  $12,227  $12,251 

Balance as of March 31, 2022

 $23  $11,712  $11,735 

 

The Company’s consolidated intangible assets consisted of the following:

 

 

December 31,

 

September 30,

  

March 31,

 

September 30,

 
 

2021

  

2021

  

2022

  

2021

 

Technology

 $12,054  $12,065  $12,081  $12,065 

Customer relationships

 1,841  1,855  1,835  1,855 

Trade name portfolio

 620  625  616  625 

Non-compete agreements

 239  244  234  244 

Patents

  72   72   72   72 
 14,826  14,861  14,838  14,861 

Accumulated amortization

  (2,575)  (2,057)  (3,103)  (2,057)
 $12,251  $12,804  $11,735  $12,804 

 

As of DecemberMarch 31, 2021,2022, future amortization expense is as follows:

 

Fiscal year ending September 30,

  

2022 (remaining nine months)

 $1,623 

2022 (remaining six months)

 1,083 

2023

 2,133  2,135 

2024

 2,119  2,122 

2025

 1,994  1,999 

2026

 1,856  1,863 

Thereafter

  2,526   2,533 

Total estimated amortization expense

 $12,251  $11,735 

 

Amortization expense was $541 and $169 for the three months ended March 31, 2022 and 2021, respectively, and $1,083 and $352 for the six months ended March 31, 2022 and 2021, respectively.

  

Three months ended

 
  

Deember 31,

 
  

2021

  

2020

 

Amortization expense

 $543  $182 

 

12

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

 

9. PREPAID EXPENSES AND OTHER

 

Prepaid expenses and other current assets consisted of the following:

 

 

December 31,

 

September 30,

  

March 31,

 

September 30,

 
 

2021

  

2021

  

2022

  

2021

 

Deposits for inventory

 $265  $997  $201  $997 

Prepaid insurance

 290  395  473  395 

Dues and subscriptions

 194  213  233  213 

Prepaid professional services

 6  158  79  158 

Prepaid commissions

 163  82  159  82 

Trade shows and travel

 178  95  143  95 

Other

  127   315   191   315 
 $1,223  $2,255  $1,479  $2,255 

 

Deposits for inventory

 

Deposits for inventory consisted of cash payments to vendors for inventory to be delivered in the future.

 

Prepaid insurance

 

Prepaid insurance consisted of premiums paid for health, commercial and corporate insurance. These premiums are amortized on a straight-line basis over the term of the agreements.

 

Dues and subscriptions

 

Dues and subscriptions consisted of payments made in advance for software subscriptions and trade and professional organizations. These payments are amortized on a straight-line basis over the term of the agreements.

 

Prepaid professional services

 

Prepaid professional services consisted of payments made in advance for services such as accounting and legal services.

 

Prepaid commissions

 

Prepaid commissions represented the current portion of sales commissions paid in connection with obtaining a contract with a customer. These costs are deferred and are amortized on a straight-line basis over the period of benefit, which is typically between three and five years. Amortization of prepaid commissions is included in selling, general and administrative expenses in the accompanying condensed consolidated statement of operations.

 

Trade shows and travel

 

Trade shows and travel consisted of payments made in advance for trade show events.

 

13

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

 

10. ACCRUED LIABILITIES AND OTHER LIABILITIES

 

Accrued liabilities consisted of the following:

 

 

December 31,

 

September 30,

  

March 31,

 

September 30,

 
 

2021

  

2021

  

2022

  

2021

 

Payroll and related

 $2,146  $3,726  $2,477  $3,726 

Deferred revenue

 1,092  1,120  982  1,120 

Customer deposits

 8,574  8,701  5,740  8,701 

Accrued contract costs

 653  416  710  416 

Warranty reserve

 146  146  150  146 

Other

  0   2   102   2 

Total

 $12,611  $14,111  $10,161  $14,111 

 

Other liabilities-noncurrent consisted of the following: 

 

 

December 31,

 

September 30,

  

March 31,

 

September 30,

 
 

2021

  

2021

  

2022

  

2021

 

Deferred extended warranty revenue

 $296  $308  $307  $308 

Asset purchase holdback liability

  699   687   723   687 

Total

 $995  $995  $1,030  $995 

 

Payroll and related

 

Payroll and related consisted primarily of accrued vacation, bonus, sales commissions and benefits.

 

Deferred revenue

 

Deferred revenue as of DecemberMarch 31, 20212022, included prepayments from customers for services, including extended warranty, scheduled to be performed in the twelve months ending DecemberMarch 31, 2022.2023.

 

Customer deposits

 

Customer deposits represent amounts paid by customers as a down payment on hardware orders to be delivered in the twelve months ending DecemberMarch 31, 2022.2023.

 

Accrued contract costs

 

Accrued contract costs consisted of accrued expenses for contracting a third-party service provider to fulfill repair and maintenance obligations required under a contract with a foreign military for units sold in the year ended September 30, 2011. Payments to the service provider will be made annually upon completion of each year of service. A new contract was signed with the customer in May 2019 to continue repair and maintenance services through May 2024. These services are being recorded in cost of revenues to correspond with the revenues for these services.

 

Warranty reserve

 

Changes in the warranty reserve and extended warranty were as follows:

 

 

December 31,

 

September 30,

  

March 31,

 

September 30,

 
 

2021

  

2021

  

2022

  

2021

 

Beginning balance

 $146  $126  $146  $126 

Warranty provision

 4  56  16  56 

Warranty settlements

  (4)  (36)  (12)  (36)

Ending balance

 $146  $146  $150  $146 

 

The Company establishes a warranty reserve based on anticipated warranty claims at the time product revenue is recognized. Factors affecting warranty reserve levels include the number of units sold, anticipated cost of warranty repairs and anticipated rates of warranty claims. The Company evaluates the adequacy of the provision for warranty costs each reporting period and adjusts the accrued warranty liability to an amount equal to estimated warranty expense for products currently under warranty.

 

14

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

Deferred extended warranty revenue

 

Deferred extended warranty revenue consisted of warranties purchased in excess of the Company’s standard warranty. Extended warranties typically range from one to two years.

 

Asset purchase holdback liability

 

In connection with the Amika Mobile asset purchase, the Company recorded a holdback liability related to potential future adjustments to assets and liabilities, misrepresentations and indemnifications against third-party claims. Adjustments of up to CAD$1,000 (USD$787799) will be deducted from the asset purchase holdback liability for up to three years from the closing date. The liability is recorded at fair value in the condensed consolidated balance sheet.

 

 

11. DEBT

 

In connection with the acquisition of Genasys Spain the Company acquired certain debts of Genasys Spain. The carrying value of the acquired debt approximates fair value. The balances of the acquired debt consist of loans with governmental agencies as of DecemberMarch 31, 2021.2022. Loans with governmental agencies represent interest free debt granted by ministries within Spain for the purpose of stimulating economic development and promoting research and development. Loans with governmental agencies as of DecemberMarch 31, 20212022 are as follows:

 

Agency

Project Name

 

Principal

  

Ministry of Economy and Competitiveness

INNPACTO 1 "eSalud"

 $17  

Ministry of Economy and Competitiveness

INNPACTO 3 "eSalud"

  273 

(a)

   $290  
  

Principal

 

Loans with governmental agencies, current portion

 $267 (a)

 

 

(a)

This loan is secured by $273$267 of cash pledged as collateral by Genasys Spain, which is the current balance of the loan. This amount is included in restricted cash atas of DecemberMarch 31, 2021.2022.  The Company expects In April 2022, the Ministry of Economy and Competitiveness to declaredeclared the terms of the loan satisfied within fiscal 2022and that the outstanding balance of the loan will bewas paid in full during fiscal 2022.with the restricted cash. Accordingly, this has been included in the current portion of notes payable as of DecemberMarch 31, 2021.2022.

The following is a schedule of future annual payments as of December 31, 2021:

2022

 $290 

Total

 $290 

 

The changes in the carrying amount of debt for the threesix months ended DecemberMarch 31, 2021,2022, are as follows:

 

Balance as of September 30, 2021

 $296  $296 

Payments

 0  (17)

Currency translation

  (6)  (12)

Balance as of December 31, 2021

 $290 

Balance as of March 31, 2022

 $267 

 

Revolving line of credit

 

On March 8, 2021, the Company entered into an agreement with MUFG Union Bank, N.A. for a $10 million revolving line of credit. Outstanding balances on the revolving line of credit bear interest at a per annum rate equal to the London Interbank Offered Rate (“LIBOR”) plus 2.25%. The agreement contains a provision for determining an alternative interest rate index in the event the LIBOR rate is no longer available. The agreement contains standard covenants, including affirmative financial covenants, such as the maintenance of a short-term liquidity ratio and a senior leverage ratio, in addition to negative covenants which limit the incurrence of additional indebtedness, loans and equity investments, disposition of assets, mergers and consolidations and other matters customarily restricted in such agreements. The maturity date of this revolving line of credit is March 31, 2023. As of DecemberMarch 31, 2021,2022, there were 0 borrowings on the revolving line of credit. The Company incurred and capitalized $38 of issuance costs related to this revolving line of credit. These issuance costs were recorded in prepaid expenses and other assets in the condensed consolidated balance sheet and have and will be amortized on a straight-line basis over the term of the loan.

 

15

Genasys Inc.
Notes to the Condensed Consolidated Financial Statements
(in thousands, except per share and share amounts)
(Unaudited)
 

12. LEASES

 

The Company determines if an arrangement is a lease at inception. The guidance in ASC 842 defines a lease as a contract, or part of a contract, that conveys the right to control the use of identified property, plant, or equipment (an identified asset) for a period of time in exchange for consideration. Operating lease ROU assets and lease liabilities are recognized based on the present value of future minimum lease payments over the lease term at commencement date. The Company’s leases do not provide an implicit rate. The Company uses its incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. Additionally, the portfolio approach is used in determining the discount rate used to present value lease payments. The ROU asset includes any lease payments made and excludes lease incentives and initial direct costs incurred.

 

15

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

The Company is party to operating leases for office and production facilities and equipment under agreements that expire at various dates through 2028. The Company elected the package of practical expedients permitted under the new lease standard. In electing the practical expedient package, the Company is not required to reassess whether an existing or expired contract is or contains a lease, reassess the lease classification for expired or existing leases nor reassess the initial direct costs for leases that commenced before the adoption of ASC 842. The Company also elected the short-term lease exemption such that the new lease standard was applied to leases greater than one year in duration. Leases with an initial term of twelve months or less are not recorded on the balance sheet. The Company recognizes lease expense for these leases on a straight-line basis over the lease term.

 

For leases beginning on or after October 1, 2019, lease components are accounted for separately from non-lease components for all asset classes. Certain of the Company’s leases contain renewal provisions and escalating rental clauses and generally require the Company to pay utilities, insurance, taxes and other operating expenses. The renewal provisions of existing lease agreements were not included in the determination of the operating lease liabilities and the ROU assets. Variable payments such as excess usage fees on existing equipment leases were not included in the determination of the lease liabilities and the ROU assets as the achievement of the specified target that triggers the variable lease payment is not considered probable. In addition, the Company’s facility lease in Spain has an escalating lease clause based on a consumer price index which is considered a variable lease payment and is not included in the determination of the lease liability and ROU asset. A 10% increase in the index would increase the total lease liability approximately $19. The Company’s leases do not contain any residual value guarantees or material restrictive covenants.

Upon adoption of ASC 842 as of October 1, 2019, the Company recognized on its consolidated balance sheet an initial measurement of approximately $7,815 of operating lease liabilities, and approximately $5,824 of corresponding operating ROU assets, net of tenant improvement allowances. There was no cumulative effect adjustment to retained earnings as a result of the transition to TASC 842. The adoption of ASC 842 did not have a material impact on the Company’s consolidated statement of operations.

During the threesix months ended DecemberMarch 31, 2021,2022, the Company added an additional operating lease ROU asset of $7 and operating lease liabilities of $7 for office equipment. The tables below show the operating lease ROU assets and liabilities as of September 30, 2021, and the balances as of DecemberMarch 31, 2021,2022, including the changes during the periods.

 

 

Operating lease

ROU assets

  

Operating lease ROU assets

 

Operating lease ROU asset as of September 30, 2021

 $4,862 

Operating lease ROU assets as of September 30, 2021

 $4,862 

Additional operating lease ROU assets

 7  7 

Less amortization of operating lease ROU assets

 (178) (360)

Effect of exchange rate on operating lease ROU assets

  (2)  (1)

Operating lease right of use asset as of December 31, 2021

 $4,689 

Operating lease ROU assets as of March 31, 2022

 $4,508 

 

16

Genasys Inc.
Notes to the Condensed Consolidated Financial Statements
(in thousands, except per share and share amounts)
(Unaudited)
 
  

Operating lease

liabilities

 

Operating lease liabilities as of September 30, 2021

 $6,608 

Additional operating lease liabilities

  7 

Less lease principal payments on operating lease liabilities

  (218)

Effect of exchange rate on operating lease liabilities

  (3)

Operating lease liabilities as of December 31, 2021

  6,394 

Less non-current portion

  (5,488)

Current portion as of December 31, 2021

 $906 

  

Operating lease liabilities

 

Operating lease liabilities as of September 30, 2021

 $6,608 

Additional operating lease liabilities

  7 

Less lease principal payments on operating lease liabilities

  (442)

Effect of exchange rate on operating lease liabilities

  (1)

Operating lease liabilities as of March 31, 2022

  6,172 

Less non-current portion

  (5,276)

Current portion as of March 31, 2022

 $896 

 

As of DecemberMarch 31, 2021,2022, the Company’s operating leases have a weighted-average remaining lease term of 6.446.21 years and a weighted-average discount rate of 4.14%. The maturities of the operating lease liabilities are as follows:

 

Fiscal year ending September 30,

    

2022 (remaining nine months)

 $866 

2022 (remaining six months)

 $578 

2023

 1,090  1,090 

2024

 1,086  1,087 

2025

 1,058  1,058 

2026

 1,071  1,071 

Thereafter

  2,139   2,139 

Total undiscounted operating lease payments

 7,310  7,023 

Less imputed interest

  (916)  (851)

Present value of operating lease liabilities

 $6,394  $6,172 

 

For the three months ended DecemberMarch 31, 20212022 and 2020,2021, total lease expense under operating leases was approximately $244$246 and $236,$245, respectively. For the six months ended March 31, 2022 and 2021, total lease expense under operating leases was approximately $491 and $490, respectively. The Company did not have any short-term lease expense during the threesix months ended DecemberMarch 31, 20212022 and 2020.2021.

16

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

 

 

13. INCOME TAXES

 

For the threesix months ended DecemberMarch 31, 2022, the Company recorded income tax benefit of $336 reflecting an effective tax rate of 28.6%. For the six months ended March 31, 2021, the Company recorded income tax benefitexpense of $291$278 reflecting an effective tax rate of 28.8%. For the three months ended December 31, 2020, the Company recorded an income tax benefit of $5 reflecting an effective tax rate of 31.2%26.4%. The Company continues to maintain a partial valuation allowance against its deferred tax assets as the Company believes that the negative evidence that it will be able to recover these net deferred tax assets outweighs the positive evidence.

 

ASC 740, Accounting for Uncertainty in Income Taxes, requires the Company to recognize in its consolidated financial statements uncertainties in tax positions taken that may not be sustained upon examination by the taxing authorities. If interest or penalties are assessed, the Company would recognize these charges as income tax expense. The Company has not recorded any income tax expense or benefit for uncertain tax positions.

 

 

14. COMMITMENTS AND CONTINGENCIES

 

Litigation

 

The Company may at times be involved in litigation in the ordinary course of business. The Company will, from time to time, when appropriate in the Company’s estimation, record adequate reserves in the Company’s consolidated financial statements for pending litigation. Currently, there are no pending material legal proceedings to which the Company is a party or to which any of its property is subject.

 

Bonus plan

 

The Company has a bonus plan for employees, in accordance with their terms of employment, whereby they can earn a percentage of their salary based on meeting targeted objectives for orders received, revenue, operating income and operating cash flow. In the threesix months ended DecemberMarch 31, 2022, the Company recorded $845 of bonus expense. In the six months ended March 31, 2021, the Company recorded $463 of bonus expense. In the three months ended December 31, 2020, the Company recorded $459$898 of bonus expense.

 

17

Genasys Inc.
Notes to the Condensed Consolidated Financial Statements
(in thousands, except per share and share amounts)
(Unaudited)

Amika Mobile asset purchase

 

In connection with the Amika Mobile asset purchase, the Company recorded a holdback liability related to potential future adjustments to assets and liabilities, misrepresentations and indemnifications against third-party claims. Adjustments of up to CAD$1,000 (USD$787799) will be deducted from the asset purchase holdback liability for up to three years from the closing date. The liability is recorded at fair value in the condensed consolidated balance sheet.

 

The Company also agreed to issue 191,267 shares of the Company’s common stock to the former owners of Amika Mobile on each of the first, second and third anniversaries of the closing date. The total number of shares of common stock the Company is obligated to issue is 573,801. The fair value of the Company’s common stock on the closing date was $5.98, resulting in the addition of $3,431 to additional paid-in-capital. During the year ended September 30, 2021, the Company accelerated the issuance of 365,109 of such shares of common stock to a former owner of the Amika Mobile assets. During the threesix months ended DecemberMarch 31, 2021,2022, the Company issued 69,564 shares to the former owners of the Amika Mobile assets. There are 139,128 remaining shares of the Company’s common stock subject to issuance under this obligation.

 

 

15. SHARE-BASED COMPENSATION

 

Stock option plans

 

As of DecemberMarch 31, 2021,2022, the Company had two equity incentive plans. The 2005 Equity Incentive Plan (“2005 Equity Plan”) was terminated with respect to new grants in March 2015 but remains in effect for grants issued prior to that time. The Amended and Restated 2015 Equity Incentive Plan (“2015 Equity Plan”) was adopted by the Company’s Board of Directors on December 6, 2016 and approved by the Company’s stockholders on March 14, 2017. The 2015 Equity Plan was amended by the Company’s Board of Directors on December 8, 2020, to increase the number of shares authorized for issuance from 5,000,000 to 10,000,000. On March 16, 2021, the Company’s stockholders approved a plan amendment. The 2015 Equity Plan authorizes the issuance of stock options, restricted stock, stock appreciation rights, restricted stock units (“RSUs”) and performance awards, to an aggregate of 10,000,000 new shares of common stock to employees, directors, advisors or consultants. As of DecemberMarch 31, 2021,2022, there were options and restricted stock units outstanding covering 70,00060,000 and 3,329,8533,300,311 shares of common stock under the 2005 Equity Plan and the 2015 Equity Plan, respectively, and 4,813,1154,525,315 shares of common stock available for grant, for a total of 8,212,9687,885,626 shares of common stock authorized and unissued under the two equity plans.

 

17

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

Share-based compensation

 

The Company’s employee stock options have various restrictions that reduce option value, including vesting provisions and restrictions on transfer and hedging, among others, and are often exercised prior to their contractual maturity.

 

There were 267,000302,000 stock options granted during the threesix months ended DecemberMarch 31, 2021.2022. There were 215,000245,000 stock options granted during the threesix months ended DecemberMarch 31, 2020.2021. The weighted average estimated fair value of employee stock options granted during the threesix months ended DecemberMarch 31, 20212022 and 2020,2022, was calculated using the Black-Scholes option-pricing model with the following weighted average assumptions (annualized percentages):

 

 

Three months ended

  

Six months ended

 
 

December 31,

  

March 31,

 
 

2021

  

2020

  

2022

  

2021

 

Volatility

 48.1%  48.6%  48.1%  48.5% 

Risk-free interest rate

 1.2%  0.6%  1.5%  0.6% 

Dividend yield

 0.0%  0.0%  0.0%  0.0% 

Expected term in years

 6.9  6.9  6.8  6.8 

 

Expected volatility is based on the historical volatility of the Company’s common stock over the period commensurate with the expected term of the options. The risk-free interest rate is based on rates published by the Federal Reserve Board. The contractual term of the options was seven years. The expected term is based on observed and expected time to post-vesting exercise. The expected forfeiture rate is based on past experience and employee retention data. Forfeitures are estimated at the time of the grant and revised in subsequent periods if actual forfeitures differ from those estimates. Such revision adjustments to expense will be recorded as a cumulative adjustment in the period in which the estimate is changed. The Company has not paid a dividend in fiscal 2022 and did not pay a dividend in fiscal 2021.

 

As of DecemberMarch 31, 2021,2022, there was approximately $1,519$1,114 of total unrecognized compensation costs related to outstanding employee stock options. This amount is expected to be recognized over a weighted average period of 1.81.6 years. To the extent the forfeiture rate is different from what the Company anticipated, stock-based compensation related to these awards will be different from the Company’s expectations.

 

18

Genasys Inc.
Notes to the Condensed Consolidated Financial Statements
(in thousands, except per share and share amounts)
(Unaudited)

Performance-based stock options

On August 1, 2016, the Company awarded a performance-based stock option (PVO) to purchase 750,000 shares of the Company’s common stock to a key executive, with a contractual term of seven years. At the grant date, there were 375,000 performance-based stock options assigned to performance criteria within each of fiscal 2019 and 2020. Vesting was based upon the achievement of certain performance criteria for each of fiscal 2019 and 2020 including a minimum free cash flow margin and net revenue targets. Additionally, vesting was subject to the executive being employed by the Company at the time the Company achieves such financial targets.

The Company determined that certain performance conditions related to the 2019 and 2020 performance criteria were achieved. 187,500 options related to the 2019 performance criteria vested and 375,000 options related to the 2020 performance criteria vested. The Company recorded a total of $459 in stock-based compensation expense for these options through September 30, 2020, in selling, general and administrative expenses in the condensed consolidated statement of operations.

 

On October 4, 2019, the Company awarded a performance-based stock option (PVO) to purchase 800,000 shares of the Company’s common stock to a key executive, with a contractual term of seven years. Vesting is based upon the achievement of certain performance criteria for each of fiscal 2022 and 2023 including a minimum free cash flow margin and net revenue targets. Additionally, vesting is subject to the executive being employed by the Company at the time the Company achieves such financial targets. The Company has not recorded stock-based compensation expense related to these options.

 

The Company did not grant any PVO’s during the threesix months ended DecemberMarch 31, 20212022 and 2020.2021.

 

Restricted stock units

During fiscal 2019, the Board of Directors granted 99,300 restricted stock units (“RSU”) to employees that will vest equally over three years on each of the firstthree anniversary dates of the grant. These were issued at a market value of $248, which have and will be expensed on a straight-line basis over the three-year life of the grants.

 

On March 10, 2020, each non-employee member of the Board of Directors received a grant of 30,000 RSUs that vested on the first anniversary of the grant date. These were issued at a market value of $425, which were expensed on a straight-line basis through the March 10, 2021 vest date. Also, in fiscal 2020, 81,270 RSUs were granted to employees that will vest over three years on the anniversary date of the grant. These were issued at a market value of $258, which have and will be expensed on a straight-line basis over the three-year life of the grants.

 

On March 16, 2021, each non-employee member of the Board of Directors received a grant of 27,883 RSUs that will vest on the first anniversary of the grant date. These were issued at a market value of $1,100, which have and will be expensed on a straight-line basis through the March 16, 2022 vest date. Also, during fiscal 2021, 145,950 RSUs were granted to employees that will vest over three years on the anniversary date of the grant. These were issued at a market value of $989, which have and will be expensed on a straight-line basis over the three-year life of the grants. On June 7, 2021, 5,000 RSUs with immediate vesting were granted to an employee at a market value of $25. These were expensed during the quarter ended June 30, 2021. On September 1, 2021, two new members of the Board of Directors received a grant of 17,500 RSUs which will vest on March 16, 2022. These were issued at a market value of $184, which have and will be expensed on a straight-line basis through the March 16, 2022 vest date.

 

DuringOn March 15, 2022, each non-employee member of the Board of Directors received a grant of 30,000 RSUs that will vest on the threefirst anniversary of the grant date. These were issued at a market value of $407, which have and will be expensed on a straight-line basis through the March 15, 2023 vest date. On November 1, 2021, 10,000 RSUs were granted to a non-employee advisor that will vest on the first anniversary of the grant date. These were issued at a market value of $51, which have and will be expensed on a straight-line basis though the November 1, 2022 vest date. Also, during the six months ended DecemberMarch 31, 2021,2022, there were 8,000100,800 RSUs granted to employees. Thatemployees that will vest over three years on the anniversary of the grant date. These were issued at a market value of $40,$348, which have and will be expensed on a straight-line basis over the three-year life of the grants.

 

Compensation expense for RSUs was $437$586 and $1,023 for the three months and six months ended DecemberMarch 31, 2021.2022, respectively. Compensation expense for RSUs was $138$249 and $387 for the three and sixmonths ended DecemberMarch 31, 2020.2021, respectively. As of March 31, 2022, there was approximately $1,181 of total unrecognized compensation costs related to outstanding RSUs. This amount is expected to be recognized over a weighted average period of 1.68 years.

 

19
18

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

A summary of the Company’s RSUs as of DecemberMarch 31, 20212022 is presented below:

 

`

 

Number of

Shares

  

Weighted

Average Grant

Date Fair Value

 
 

Number of

Shares

  

Weighted

Average Grant

Date Fair Value

 

Outstanding September 30, 2021

 399,469  $6.27  399,469  $6.27 

Granted

 8,000  $4.99  260,800  $3.09 

Released

 0  $0  (262,342) $6.46 

Forfeited/cancelled

  (5,000) $5.05   (15,000) $5.05 

Outstanding December 31, 2021

  402,469  $6.26 

Outstanding March 31, 2022

  382,927  $4.03 

 

Stock option summary information

 

A summary of the activity in options to purchase the capital stock of the Company as of DecemberMarch 31, 20212022 is presented below:

 

  

Number of

Shares

  

Weighted

Average

Exercise Price

 

Outstanding September 30, 2021

  2,745,384  $3.02 

Granted

  267,000  $4.99 

Forfeited/expired

  0  $0 

Exercised

  (15,000) $3.06 

Outstanding December 31, 2021

  2,997,384  $3.20 

Exerciseable December 31, 2021

  1,562,503  $2.29 

  

Number of

Shares

  

Weighted

Average

Exercise Price

 

Outstanding September 30, 2021

  2,745,384  $3.02 

Granted

  302,000  $4.87 

Forfeited/expired

  0  $0 

Exercised

  (70,000) $2.43 

Outstanding March 31, 2022

  2,977,384  $3.23 

Exerciseable March 31, 2022

  1,562,503  $2.42 

 

Options outstanding are exercisable at prices ranging from $1.31 to $8.03 per share and expire over the period from 2022 to 2028 with an average life of 3.863.72 years. The aggregate intrinsic value of options outstanding and exercisable as of DecemberMarch 31, 20212022 was $3,373$1,067 and $2,816,$1,067, respectively. The aggregate intrinsic value represents the difference between the Company’s closing stock price on the last day of trading for the quarter, which was $3.98$2.75 per share, and the exercise price multiplied by the number of applicable options. The total intrinsic value of stock options exercised during the threesix months ended DecemberMarch 31, 20212022 was $74$86 and proceeds from these exercises was $46.$170. The total intrinsic value of stock options exercised during the threesix months ended DecemberMarch 31, 20202021 was $113$455 and proceeds from these exercises was $54.$170.

 

The following table summarized information about stock options outstanding atas of DecemberMarch 31, 2021:2022:

 

       

Weighted Average

 

Weighted Average

     

Weighted Average

       

Weighted Average

 

Weighted Average

     

Weighted Average

 

Range of

Range of

 

Number

 

Remaining

 

Exercise

 

Number

 

Exercise

 

Range of

 

Number

 

Remaining

 

Exercise

 

Number

 

Exercise

 

Exercise Prices

Exercise Prices

 

Outstanding

  

Contractual Term

  

Price

  

Exercisable

  

Price

 

Exercise Prices

 

Outstanding

 

Contractual Term

 

Price

 

Exercisable

 

Price

 
$1.31-

$1.86

 324,157  1.75  $1.64  324,157  $1.64 -$1.86 319,157  1.51  $1.64  319,157  $1.64 
$1.99-

$1.99

 937,500  2.18  $1.99  937,500  $1.99 -$1.99 937,500  1.94  $1.99  937,500  $1.99 
$2.16-

$2.90

 50,000  0.19  $2.31  50,000  $2.31 
$3.39-

$3.39

 800,000  4.76  $3.39  0  $0 -$3.39 800,000  4.51  $3.39  0  $0 
$3.40-

$8.03

  885,727   5.81  $4.93   250,846  $4.27 -$4.99 635,727  5.53  $4.10  237,745  $3.60 

$5.05

-$8.03  285,000   5.80  $6.66   80,780  $6.94 
    2,997,384   3.86  $3.20   1,562,503  $2.29    2,977,384   3.72  $3.23   1,575,182  $2.42 

 

The Company recorded $120$151 and $44$79 of stock option compensation expense for employees, directors and consultants for the three months ended DecemberMarch 31, 2021,2022, and 2020,2021, respectively. The Company recorded $272 and $123 of stock option compensation expense for employees, directors and consultants for the six months ended March 31, 2022, and 2021, respectively.

 

20
19

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

Share-based compensation

 

The Company recorded share-based compensation expense and classified it in the condensed consolidated statements of operations as follows:

 

  

Three Months Ended

 
  

December 31,

 
  

2021

  

2020

 

Cost of revenues

 $15  $5 

Selling, general and administrative

  531   171 

Research and development

  12   6 
  $558  $182 

  

Three Months Ended

  

Six Months Ended

 
  

March 31,

  

March 31,

 
  

2022

  

2021

  

2022

  

2021

 

Cost of revenues

  28  $9   43   15 

Selling, general and administrative

  686   309   1,217   479 

Research and development

  23   10   35   16 
  $737  $328  $1,295  $510 

 

 

16. STOCKHOLDERS EQUITY

 

Summary

 

The following table summarizes changes in the components of stockholders’ equity during the threesix months ended DecemberMarch 31, 20212022 and the threesix months ended DecemberMarch 31, 20202021 (amounts in thousands, except par value and share amounts):

 

                 

Accumulated

                     

Accumulated

    
 

Common Stock

 

Additional

     

Other

 

Total

  

Common Stock

 

Additional

     

Other

 

Total

 
 

Shares

  

Par Value

Amount

  

Paid-in

Capital

  

Accumulated

Deficit

  

Comprehensive

Loss

  

Stockholders'

Equity

  

Shares

  

Par Value Amount

  

Paid-in Capital

  

Accumulated Deficit

  

Comprehensive Loss

  

Stockholders' Equity

 

Balance as of September 30, 2021

 36,403,833  $364  $107,110  $(41,154) $2  $65,958  36,403,833  $364  $107,110  $(41,154) $2  $65,958 

Share-based compensation expense

 -  0  558  0  0  558  -  0  558  0  0  558 

Issuance of common stock upon exercise of stock options, net

 15,000  0  46  0  0  46  15,000  0  46  0  0  46 

Stock buyback

 (116,868) (1) (441) 0  0  (441) (116,868) (1) (441) 0  0  (441)

Release of obligation to issue commons stock

 69,564  0  0  0  0  0  69,564  0  0  0  0  0 

Accumulated other comprehensive loss

 -  0  0  0  (85) (85) -  0  0  0  (85) (85)

Net loss

  -   0   0   (1,305)  0   (1,305)  -   0   0   (1,305)  0   (1,305)

Balance as of December 31, 2021

  36,371,529  $363  $107,273  $(42,459) $(83) $64,731   36,371,529  $363  $107,273  $(42,459) $(83) $64,731 
             

Share-based compensation expense

 -  0  737  0  0  737 

Issuance of common stock upon exercise of stock options, net

 55,000  1  124  0  0  124 

Issuance of common stock upon vesting of restricted stock units

 262,342  2  0  0  0  0 

Shares retained for payment of taxes in connection with net share settlement of restricted stock units

 (18,344) 0  (70) 0  0  (70)

Stock buyback

 (142,442) (1) (557) 0  0  (557)

Accumulated other comprehensive loss

 -  0  0  0  (1) (1)

Net loss

  -   0   0   (492)  0   (492)

Balance as of March 31, 2022

  36,528,085  $365  $107,507  $(42,951) $(84) $64,472 

 

                  

Accumulated

     
  

Common Stock

  

Additional

      

Other

  

Total

 
  

Shares

  

Par Value

Amount

  

Paid-in

Capital

  

Accumulated

Deficit

  

Comprehensive

Loss

  

Stockholders'

Equity

 

Balance as of September 30, 2020

  33,561,544  $336  $91,248  $(41,858) $(250) $49,140 

Share-based compensation expense

  -   0   182   0   0   182 

Issuance of common stock upon exercise of stock options, net

  25,899   0   54   0   0   54 

Obligation to issue common stock

  -   0   3,431   0   0   3,431 

Accumulated other comprehensive income

  -   0   0   0   469   469 

Net loss

  -   0   0   (619)  0   (619)

Balance as of December 31, 2020

  33,587,443  $336  $94,915  $(42,477) $219  $52,657 
20

 

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

                  

Accumulated

     
  

Common Stock

  

Additional

      

Other

  

Total

 
  

Shares

  

Par Value Amount

  

Paid-in Capital

  

Accumulated Deficit

  

Comprehensive Loss

  

Stockholders' Equity

 

Balance as of September 30, 2020

  33,561,544  $336  $91,248  $(41,858) $(250) $49,140 

Share-based compensation expense

  -   0   182   0   0   182 

Issuance of common stock upon exercise of stock options, net

  25,899   0   54   0   0   54 

Obligation to issue common stock

  -   0   3,431   0   0   3,431 

Accumulated other comprehensive income

  -   0   0   0   469   469 

Net loss

  -   0   0   (619)  0   (619)

Balance as of December 31, 2020

  33,587,443  $336  $94,915  $(42,477) $219  $52,657 
                         

Share-based compensation expense

  -  $0  $328  $0  $0  $328 

Issuance of common stock upon exercise of stock options, net

  60,563   1   116   0   0   116 

Issuance of common stock upon vesting of restricted stock units

  223,633   2   0   0   0   0 

Shares retained for payment of taxes in connection with net share settlement of restricted stock units

  (22,073)  0   (141)  0   0   (141)

Accumulated other comprehensive loss

  -   0   0   0   (78)  (78)

Net income

  -   0   0   262   0   262 

Balance at March 31, 2021

  33,849,566  $339  $95,218  $(42,215) $141  $53,144 

 

Common stock activity

 

During the threesix months ended DecemberMarch 31, 2021,2022, the Company issued 15,00070,000 shares of common stock and received gross proceeds of $46$170 in connection with the exercise of stock options.options and the Company issued 243,998 shares of common stock in connection with the vesting of RSUs. During the threesix months ended DecemberMarch 31, 2020,2021, the Company issued 25,89986,462 shares of common stock and received gross proceeds of $54$170 in connection with the exercise of stock options.options and the Company issued 201,560 shares of commons stock in connection with the vesting of RSUs.

 

In connection with the Amika Mobile asset purchase, the Company agreed to issue 191,267 shares of the Company’s common stock to the former owners of Amika Mobile on each of the first, second and third anniversaries of the closing date. The total number of shares of common stock the Company is obligated to issue is 573,801. The fair value of the Company’s common stock on the closing date was $5.98, resulting in the addition of $3,431 to additional paid-in-capital. During the year ended September 30, 2021, the Company accelerated the issuance of 365,109 of such shares of common stock to a former owner of the Amika Mobile assets. During the threesix months ended DecemberMarch 31, 2021,2022, the Company issued 69,564 shares to the former owners of the Amika Mobile assets. There are 139,128 remaining shares of the Company’s common stock subject to issuance under this obligation.

 

Share buyback program

 

In December 2018, the Board of Directors approved a new share buyback program beginning January 1, 2019 and expiring on December 31, 2020, under which the Company was authorized to repurchase up to $5 million of its outstanding common shares. In December 2020, the Board of Directors extended the buyback program until December 31, 2022. The previous program expired on December 31, 2018.

 

21

Genasys Inc.
Notes to the Condensed Consolidated Financial Statements
(in thousands, except per share and share amounts)
(Unaudited)

During the threesix months ended DecemberMarch 31, 2021,2022, 116,868259,310 shares were repurchased for $441.$998. There were 0 shares repurchased during the threesix months ended DecemberMarch 31, 2020.2021. As of March 31, 2022, all repurchased shares were retired.

 

Dividends

 

There were 0 dividends declared in the threesix months ended DecemberMarch 31, 20212022 and 2020.2021.

21

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

 

 

17. NET LOSS(LOSS) INCOME PER SHARE

 

The following table sets forth the computation of basic and diluted net loss(loss) income per share:

 

  

Three months ended

 
  

December 31,

 
  

2021

  

2020

 

Net loss

 $(1,305) $(619)
         

Basic loss per share

 $(0.04) $(0.02)

Diluted loss per share

 $(0.04) $(0.02)
         

Weighted average shares outstanding - basic

  36,456,187   33,573,755 

Weighted average shares outstanding - diluted

  36,456,187   33,573,755 
         

Potentially diluted securities outstanding at period end excluded from diluted computation as the inclusion would have been antidilutive:

        

Options

  2,997,384   2,754,281 

RSU

  402,469   302,737 

Obligation to issue common stock

  139,128   0 

Total

  3,538,981   3,057,018 

  

Three months ended

  

Six months ended

 
  

March 31,

  

March 31,

 
  

2022

  

2021

  

2022

  

2021

 

Net (loss) income

 $(492) $262  $(1,797) $(357)
                 

Basic (loss) income per share

 $(0.01) $0.01  $(0.05) $(0.01)

Diluted (loss) income per share

 $(0.01) $0.01  $(0.05) $(0.01)
                 

Weighted average shares outstanding - basic

  36,353,321   33,683,240   36,405,321   33,629,479 

Assumed exercise of dilutive options

  0   1,096,026   0   0 

Weighted average shares outstanding - diluted

  36,353,321   34,779,266   36,405,321   33,629,479 
                 

Potentially diluted securities outstanding at period end excluded from diluted computation as the inclusion would have been antidilutive:

                

Options

  2,977,384   830,000   2,977,384   2,723,718 

RSU

  382,927   0   382,927   325,669 

Obligation to issue common stock

  139,128   0   139,128   0 

Total

  3,499,439   830,000   3,499,439   3,049,387 

 

 

18. SEGMENT INFORMATION

 

The Company is engaged in the design, development and commercialization of directed and multidirectional sound technologies, voice broadcast products, and location-based mass messaging solutionssoftware for emergency warning and workforceevacuation management. The Company operates in 2 business segments: Hardware and Software and its principal markets are North and South America, Europe, the Middle East and Asia. As reviewed by the Company’s chief operating decision maker, the Company evaluates the performance of each segment based on sales and operating income. Cash and cash equivalents, marketable securities, accounts receivable, inventory, property and equipment, deferred tax assets, goodwill and intangible assets are primary assets identified by segment. The accounting policies for segment reporting are the same for the Company as a whole and transactions between the 2 operating segments are not material.whole.

 

22

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

The following table presents the Company’s segment disclosures:

 

 

Three months ended

  

Three months ended

 

Six months ended

 
 

December 31,

  

March 31,

 

March 31,

 
 

2021

  

2020

  

2022

  

2021

  

2022

  

2021

 
          

Revenue from external customers

          

Hardware

 $10,127  $7,387  $12,495  $10,625  $22,622  $18,012 

Software

  550   641   673   676   1,223   1,317 
 $10,677  $8,028  $13,168  $11,301  $23,845  $19,329 
          

Intersegment revenues

          

Hardware

 $0  $0  $0  $0  0  $0 

Software

  674   351   820   254   1,494   606 
 $674  $351  $820  $254  $1,494  $606 
          

Segment operating income (loss)

          

Hardware

 $1,172  $508  $2,537  $1,796  $3,709  $2,304 

Software

  (2,781)  (1,201)  (3,064)  (1,243)  (5,845)  (2,444)
 $(1,609) $(693) $(527) $553  $(2,136) $(140)
          

Other expenses:

          

Depreciation and amortization expense

          

Hardware

 $90  $90  $96  $93  $190  $183 

Software

  549   191   547   177   1,092   369 
 $639  $281  $643  $270  $1,282  $552 
          

Income tax benefit

 

Income tax expense (benefit)

         

Hardware

 $(291) $(5) $726  $412  $1,066  $531 

Software

  0   0   (771)  (129)  (1,402)  (253)
 $(291) $(5) $(45) $283  $(336) $278 

 

  

December 31,

  

September 30,

 
  

2021

  

2021

 

Long-lived assets

        

Hardware

 $1,799  $1,748 

Software

  36,060   36,645 
  $37,859  $38,393 
         

Total assets

        

Hardware

 $48,782  $50,364 

Software

  38,498   39,764 
  $87,280  $90,128 

  

March 31,

  

September 30,

 
  

2022

  

2021

 

Long-lived assets

        

Hardware

 $1,706  $1,748 

Software

  35,585   36,645 
  $37,291  $38,393 
         

Total assets

        

Hardware

 $47,237  $50,364 

Software

  37,821   39,764 
  $85,058  $90,128 

 

 

19. MAJOR CUSTOMERS, SUPPLIERS AND RELATED INFORMATION

 

For the three months ended DecemberMarch 31, 2021,2022, revenues from 2 customers accounted for 63% and 13% of total revenues with no other single customer accounting for more than 10% of revenues. For the six months ended March 31, 2022, revenues from one customer accounted for 68%65% of total revenues with no other single customer accounting for more than 10% of revenues. As of DecemberMarch 31, 2021,2022, accounts receivable from two customers accounted for 61%56% and 23% of total accounts receivable, with no other single customer accounting for more than 10% of the accounts receivable balance.

For the three months ended December 31, 2020, revenues from one customer accounted for 52% of total revenues with no other single customer accounting for more than 10% of revenues. As of December 31, 2020, accounts receivable from three customers accounted for 48%, 14% and 10%17% of total accounts receivable, with no other single customer accounting for more than 10% of the accounts receivable balance.

 

23

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

For the three months ended March 31, 2021, revenues from one customer accounted for 47% of total revenues with no other single customer accounting for more than 10% of revenues. For the six months ended March 31, 2021, revenues from 1 customer accounted for 49% of total revenues with no other single customer accounting for more than 10% of revenues. As of March 31, 2021, accounts receivable from 2 customers accounted for 33% and 25% of total accounts receivable, with no other single customer accounting for more than 10% of the accounts receivable balance.

Revenue from customers in the United States was $9,303$9,531 and $8,086 for the three months ended DecemberMarch 31, 2021.2022 and 2021, respectively. Revenue from customers in the United States was $5,712$18,769 and $13,837 for the threesix months ended DecemberMarch 31, 2020.2022 and 2021, respectively. The following table summarizes revenues by geographic region. Revenues are attributed to countries based on customer’s delivery location. The following table summarizes revenues by geographic region.

 

 

Three months ended

 

Six months ended

 
 

Three months ended December 31,

  

March 31,

 

March 31,

 
 

2021

  

2020

  

2022

  

2021

  

2022

  

2021

 

Americas

 $9,436  $6,014  $10,095  $8,598  $19,531  $14,406 

Asia Pacific

 308  1,011  2,147  2,213  2,455  3,223 

Europe, Middle East and Africa

  933   1,003   926   490   1,859   1,700 

Total Revenues

 $10,677  $8,028  $13,168  $11,301  $23,845  $19,329 

 

The following table summarizes long lived assets by geographic region.

 

  

December 31,

  

September 30,

 
  

2021

  

2021

 

United States

 $26,552  $26,880 

Americas (excluding the United States)

  8,313   8,395 

Europe, Middle East and Africa

  2,994   3,118 

Total long lived assets

 $37,859  $38,393 
  

March 31,

  

September 30,

 
  

2022

  

2021

 

United States

 $26,078  $26,880 

Americas (excluding the United States)

  8,330   8,395 

Europe, Middle East and Africa

  2,883   3,118 

Total long lived assets

 $37,291  $38,393 

 

24
24

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

 

 

Item 2.          Managements Discussion and Analysis of Financial Condition and Results of Operations

 

The discussion and analysis set forth below should be read in conjunction with the accompanying unaudited condensed consolidated financial statements and the related notes included under Item 1 of this Quarterly Report on Form 10-Q, together with Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended September 30, 2021.

 

Forward Looking Statements

 

This report contains certain statements of a forward-looking nature relating to future events or future performance. Words such as expects, anticipates, intends, plans, believes, seeks, estimates and similar expressions or variations of such words are intended to identify forward-looking statements but are not the only means of identifying forward-looking statements. Prospective investors are cautioned that such statements are only predictions and actual events or results may differ materially. In evaluating such statements, prospective investors should specifically consider various factors identified in this report and any matters set forth under Part I, Item 1A (Risk Factors) of our Annual Report on Form 10-K, which could cause actual results to differ materially from those indicated by such forward-looking statements.

 

For purposes of this Quarterly Report, the terms we, us, our Genasys and the Company refer to Genasys Inc. and its consolidated subsidiaries.

 

Overview

Genasys is a global provider of critical communications hardware and software solutionssystems designed to alert and inform to help keep people safe. Our unified platform receives information from a wide variety of sensors and Internet-of-Things (IoT) inputs to collect real-time information on developing and active emergency situations. Genasys uses this information to create and disseminate alerts, warnings, notifications, and instructions through multiple channels before, during, and after public safety and enterprise threats, critical events, and other crisis situations.

 

Our multi-channel approach includes:

 

Genasys Emergency Management (GEM) is Genasys’ software-based product platform. The GEM product line consists of GEM Software, IMNS, and Zonehaven.

 

GEM Software is an interactive, cloud-based SaaS solution that sends at-risk individuals or groups critical information when an emergency occurs. GEM Software acts as both a communications input and output, receiving information from state-of-the-art sensors and emergency services, and quickly relaying notifications, alerts, and instructions to at-risk populations and first responders. GEM Software operators can create and send critical, verified, and secure notifications and messages using emails, voice calls, text messages, panic buttons, desktop alerts, television, social media, and more.

 

Integrated Mass Notification System (IMNS) is Genasys’ comprehensive emergency response solution, uniting GEM Software and Genasys speaker system hardware in a multichannel solution. IMNS gives operators the ability to communicate critical notifications across platforms using a command and control interface that can be accessed from an emergency operations center, authorized computer, or smart phone. Notifications can be sent using text messages, emails, IPAWS, desktop alerts, television, voice calls, social media, and Genasys speaker systems. By providing several digital, software-based notifications and audible voice alerts through speakers, IMNS creates layered redundancy to enable the maximum number of people receive critical communications.

 

Zonehaven is a multipronged SaaS application that serves both first responders and the communities they protect. Zonehaven can function as a standalone application or as a GEM Software integration. When an incident occurs, it is immediately tracked by the Zonehaven platform, which maps the incident, simulates the speed and direction of the incident, and determines which zones (geographic areas) are at risk and need to be evacuated. As an incident develops, Zonehaven’s real-time updates provide emergency organizations and at-risk populations up-to-date information to stay safe.

 

National Emergency Warning System (NEWS) provides multichannel public safety notifications and instructions to designated areas, groups, or agencies when a crisis occurs. The NEWS platform is cloud-based, geo-redundant, and end-to-end encrypted. NEWS is a SaaS product that requires mobile telecom services for installation, integration and to deliver Location-based SMS and Cell Broadcast alerts and notifications that can be sent to anyone, anywhere, with no recipient opt-in, registration, or download required. NEWS can locate recipients and deliver messages in near real time, compared to other SMS alert providers that can take up to 15 minutes. Despite NEWS’ reach and scope, all data is anonymized, helping

National Emergency Warning System (NEWS) provides multichannel public safety notifications and instructions to designated areas, groups, or agencies when a crisis occurs. The NEWS platform is cloud-based, geo-redundant, and end-to-end encrypted. NEWS is a SaaS product that requires mobile telecom services for installation, integration and to deliver Location-based SMS and Cell Broadcast alerts and notifications that can be sent to anyone, anywhere, with no recipient opt-in, registration, or download required. NEWS can locate recipients and deliver messages in near real time, while other SMS alert providers can take up to 15 minutes. NEWS’ data is anonymized to help individuals stay safe and informed without sacrificing privacy.

 

25

 

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

LRAD is the world’s leading Acoustic Hailing Device (AHD) that projects siren tones and audible voice messages with exceptional vocal clarity in a 30° beam from close range to 5,500 meters. LRADs are used throughout the world in multiple applications and circumstances to safely hail and warn, inform and direct, prevent misunderstandings, determine intent, establish large safety zones, resolve uncertain situations, and save lives.

 

Our critical communications systems are being used in more than 100 countries throughout the world in a range of diverse applications includingthat include public safety, emergency warning, mass notification, defense, law enforcement, critical event managementinfrastructure protection and many more. We continue to develop new communication innovations and believe we have established significant competitive advantages in our principal markets. 

 

Business developments in the fiscal quarter ended DecemberMarch 31, 2021:2022:

 

 

Announced GEM SoftwareGenasys NEWS selected by the country of Slovenia to power nationwide public warning system

Expanded Zonehaven evacuation software services contracts in five U.S. States announcedand alerting resources into Los Angeles and four additional California Counties

Awarded $1.97 million public safety mass notification and emergency warning systems contract from the City of Berkeley, California

 

 

Announced Zonehaven evacuationmultiple critical communications software services contracts with 13 California counties announcedin Texas

 

 

Received a follow-on GEM SoftwareAwarded contract in the public safety category from a global automaker for operations in a Latin America country received

Announced GEM Enterprise is providing emergency and operations communications for The Green Bay Packers and Lambeau Field

Received $1.9 million in LRAD international defense and wildlife preservation orders received

Received a follow-on $1.8 million LRAD order under a previously announced U.S. Navy IDIQ contract received

Partnered with Danimex Communication to expand hardware and software sales in AfricaSourcewell

 

Revenues for the Company’s firstsecond quarter of fiscal 2022, were $10.7$13.2 million, an increase from $8.0$11.3 million in the firstsecond quarter of fiscal 2021. Both LRAD ($7.510.6 million) and IMNS ($2.61.9 million) revenues increased $0.4 million$819 and $2.3 million,$1,054, respectively, offset by a $0.1 million$6 decrease in software revenue ($0.6 million)673) compared towith the prior year quarter. The timing of budget cycles, government financial issues and military conflict in certain areas of the world, often delay contract awards, resulting in uneven quarterly revenues. Gross profit increased compared to the same quarter in the prior year as a result of higher sales offset by increased software engineering expenses. Operating expenses in the quarter ended DecemberMarch 31, 2021,2022, increased 47.9%59.3% to $6.5$7.5 million, compared to $4.4with $4.7 million in the same period in the prior year. We reported a net loss of $1.3 million$492 for the firstsecond quarter of fiscal 2022, or a loss of $0.04$0.01 per share, compared to awith net lossincome of $0.6 million,$262, or a loss of $0.02$0.01 per share, for the same quarter in the prior year.

 

Overall Business Outlook

Our products, systems and solutions continue to gain worldwide awareness and recognition through media exposure, product demonstrations, and word of mouth as a result of positive responses and increased acceptance. We believe we have a solid global brand, technology, and product foundation, which we continue to expand to serve new markets and customers for greater business growth.  We believe we have strong market opportunities for our product offerings throughout the world in the defense, public safety, emergency warning, mass notification, critical event managementinfrastructure protection, and law enforcement sectors as a result of increasing threats to government, commerce, homeland security, and critical infrastructure. Our products, systems and solutions also have many applications within the fire rescue, maritime, asset protection, and wildlife preservation business segments.

 

Genasys has developed a global market and an increased demand for LRAD AHDs and advanced outdoor mass notification speakers. We have a reputation for producing quality products that feature industry leading broadcast area coverage, vocal intelligibility, and product reliability. We intend to continue building on our AHD leadership position by offering enhanced voice broadcast systems and accessories for an expanding range of applications. In executing our strategy, we use direct sales to governments, militaries, large end-users, system integrators, and prime vendors. We have built a worldwide distribution channel consisting of partners and resellers that have significant expertise and experience selling integrated communication solutions into our various target markets. As our primary AHD sales opportunities are with domestic and international governments, military branches, and law enforcement agencies, we are subject to each customer’s unique budget cycle, which leads to long selling cycles and uneven revenue flow, complicating our product planning. 

 

26

 

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

The proliferation of natural and man-made disasters, emergency events, and civil unrest and military conflict require technologically advanced, multichannel solutions to deliver clear and timely critical communications to help keep people safe during crisis situations. Businesses are also incorporating critical communication and emergency management systems that locate and help safeguard employees when crises occur.

 

By providing the only SaaS platform that unifies sensors and IoT inputs with multichannel, multiagency alerting and notifications, Genasys seeks to deliver reliable, fast, and intuitive solutions for creating and disseminating geolocation-targeted warnings, information, and instructions before, during, and after public safety and business threats, critical events, and other life safety situations.

 

While the mass notification market is more mature with many established manufacturers and suppliers, we believe that our advanced technology and unified platform provides opportunities to succeed in the large and growing public safety, emergency warning, and critical communications markets.

 

In fiscal 2022, we intend to continue to pursue domestic and international business opportunities with the support of business development consultants, key representatives, and resellers. We plan to grow our revenue through increased direct sales to governments and agencies that desire to integrate our communication technologies into their defense, homeland security and public safety systems. This includes building on fiscal 2021 domestic defense sales by pursuing further U.S. military opportunities. We also plan to pursue emergency warning, public safety and enterprise and critical event management,communications, government, law enforcement, fire rescue, homeland and international security, private and commercial security, border security, maritime security, and wildlife preservation business opportunities.

 

Our research and development strategy involves incorporating further innovations and capabilities into our GEM, IMNS, Zonehaven, NEWS and LRAD products, systems and solutions to meet the needs of our target markets.

 

Our GEM, IMNS, Zonehaven and NEWS software solutions represent more complex, integrated offerings. We are pursuing certain certifications, which are often required when bidding on government and mass notification opportunities. We intend to invest engineering resources to enhance our GEM, IMNS, Zonehaven and NEWS software solutions to compete for larger emergency warning and critical communications business opportunities. We are also configuring alternative solutions to achieve lower price points to meet the needs of certain customers or applications. We also engage in ongoing value engineering to reduce the cost and simplify the manufacturing of our products.

 

In March 2020, the World Health Organization ("WHO") classified the COVID-19 outbreak as a pandemic. While the impact of the COVID-19 pandemic did not have a material adverse effect on our financial position or results of operations for the ninesix months ended June 30, 2021,March 31, 2022, we monitor the developments and assess areas where there is potential for our business to be impacted. A significant portion of our sales force is working remotely, which could, among other things, negatively impact our ability to engage in sales-related initiatives, or efficiently conduct day-to-day operations. Other businessesBusinesses and governments with which we engage are likelymay be operating under similar restrictions and experiencing disruptions, which may create obstacles in the coordination of business activities, including the negotiation and fulfillment of orders. Disruptions in the supply chain could negatively impact our ability to source materials or manufacture and distribute products. While we do not currently anticipate a material reduction in demand for our commercialized products, we could experience a decrease in new orders, which could negatively impact our revenues and reduce our liquidity and cash flows. Growth in revenue could also be impeded by these factors. The financial markets have been subject to significant volatility that could impact our ability to enter into, modify, and negotiate favorable terms and conditions relative to equity and debt financing activities. We have $10.1$10.3 million in cash and cash equivalents as of DecemberMarch 31, 2021,2022, which we believe provides sufficient capital to fund our operations for at least the next twelve months and withstand the potential near-term consequences of the pandemic, although liquidity constraints and access to capital markets could adversely impact our liquidity and warrant changes to our investment strategy. While we have not yet experienced a material impact, the full magnitude of the pandemic cannot be measured at this time, and therefore, any of the aforementioned circumstances, as well as other factors, may cause our results of operations to vary substantially from year to year and quarter to quarter.

 

Based on various standards published to date, we believe the work our associates perform is critical, essential and life sustaining. We are taking a variety of measures to promote the safety and security of our employees while ensuring the availability and functionality of our critical infrastructure. We are following Center for Disease Control and local guidelines to reduceregarding COVID-19 safety in the transmission of COVID-19, such as the imposition of travel restrictions, cancellation of events, the promotion of social distancing, the adoption of work-from-home arrangements, and limiting access to our facilities. Some or all of these policies and initiatives could impact our operations.workplace. In addition, the following events related to the COVID-19 pandemic could result in lost or delayed revenue to the Company: limitations on the ability of our suppliers to meet delivery requirements and commitments; limitations on the ability of our employees to perform their work due to illness caused by the pandemic, or local, state or federal orders requiring employees to remain at home; limitations on the ability of carriers to deliver our products to customers; unforeseen deviations from customers or foreign governments restricting the ability to do business; and, limitations on the ability of our customers to pay us on a timely basis, if at all.

 

27

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

 

A large number of components and sub-assemblies manufactured by outside suppliers within our supply chain are produced within 50 miles of our facility. We do not source component parts directly from suppliers in China, however, it is likely that some of our suppliers source parts in China. The COVID-19 pandemic has adversely impacted worldwide supply chains and the ability to obtain sufficient amounts of component parts, including semiconductor chips and integrated circuits, resins, coating and other equipment and components. Negative impacts on our supply chain could have a material adverse effect on our business. We are in contact with our suppliers and evaluating what impact may result from COVID-19.

 

Critical Accounting Policies

 

We have identified a number of accounting policies as critical to our business operations and the understanding of our results of operations. These are described in our consolidated financial statements located in Management’s Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended September 30, 2021. The impact and any associated risks related to these policies on our business operations is discussed below and throughout Management’s Discussion and Analysis of Financial Condition and Results of Operations when such policies affect our reported and expected financial results.

 

The methods, estimates and judgments we use in applying our accounting policies, in conformity with U.S. generally accepted accounting principles, have a significant impact on the results we report in our financial statements. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. The estimates affect the carrying values of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.

 

28

Comparison of Results of Operations for the Three Months Ended DecemberMarch 31, 20212022 and 20202021 (in thousands)

 

 

Three Months Ended

         

Three Months Ended

         
 

December 31, 2021

 

December 31, 2020

         

March 31, 2022

  

March 31, 2021

         
     

% of

     

% of

             

% of

     

% of

        
     

Total

     

Total

 

Fav(Unfav)

      

Total

     

Total

 

Fav(Unfav)

 
 

Amount

  

Revenue

  

Amount

  

Revenue

  

Amount

  

%

  

Amount

  

Revenue

  

Amount

  

Revenue

  

Amount

  

%

 

Revenues:

              

Product sales

 $9,570  89.6% $6,950  86.6% $2,620  37.7% $11,854  90.0% $10,131  89.6% $1,723  17.0%

Contract and other

  1,107  10.4%  1,078  13.4%  29  2.7%  1,314  10.0%  1,170  10.4%  144  12.3%

Total revenues

 10,677  100.0% 8,028  100.0% 2,649  33.0% 13,168  100.0% 11,301  100.0% 1,867  16.5%
              

Cost of revenues

  5,783  54.2%  4,324  53.9%  (1,459) (33.7%)  6,208  47.1%  6,047  53.5%  (161) (2.7%)

Gross Profit

 4,894  45.8% 3,704  46.1% 1,190  32.1%

Gross profit

 6,960  52.9% 5,254  46.5% 1,706  32.5%
              

Operating expenses

              

Selling, general and administrative

 5,134  48.1% 3,331  41.5% (1,803) (54.1%) 5,594  42.5% 3,824  33.8% (1,770) (46.3%)

Research and development

  1,369  12.8%  1,066  13.3%  (303) (28.4%)  1,893  14.4%  877  7.8%  (1,016) (115.8%)

Total operating expenses

  6,503  60.9%  4,397  54.8%  (2,106) (47.9%)  7,487  56.9%  4,701  41.6%  (2,786) (59.3%)
              

Loss from operations

 (1,609) (15.1%%) (693) (8.6%) (916) 132.2%

(Loss) income from operations

 (527) (4.0%) 553  4.9% (1,080) (195.3%)
              

Other income, net

  13  0.1%  69  0.9%  (56) (81.2%)

Other income (expense), net

  (10) (0.1%)  (8) (0.1%)  (2) 25.0%
              

Loss before income taxes

 (1,596) (14.9%) (624) (7.8%) (972) 155.8%

Income tax benefit

  (291) (2.7%)  (5) (0.1%)  286  (5,720.0%)

Net loss

 $(1,305) (12.2%) $(619) (7.7%) $(686) 110.8%

(Loss) income before income taxes

 (537) (4.1%) 545  4.8% (1,082) (198.5%)

Income tax (benefit) expense

  (45) (0.3%)  283  2.5%  328  115.9%

Net (loss) income

 $(492) (3.7%) $262  2.3% $(754) (287.8%)
              

Net revenue

              

Hardware

 $10,127  94.8% $7,387  92.0% 2,740  37.1% $12,495  94.9% $10,625  94.0% 1,870  17.6%

Software

  550  5.2%  641  8.0%  (91) (14.2%)  673  5.1%  676  6.0%  (3) (0.4%)

Total net revenue

 $10,677  100.0% $8,028  100.0% $2,649  33.0% $13,168  100.0% $11,301  100.0% $1,867  16.5%

 

The tables above set forth for the periods indicated certain items of our condensed consolidated statements of operations expressed in dollars and as a percentage of net revenues. The financial information and the discussion below should be read in conjunction with the condensed consolidated financial statements and notes contained in this report.

 

28

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

Revenues

 

Revenues increased $2,649$1,867, or 33%16.5%, compared towith the same quarter in the prior year. LRAD revenues ($7,512)10,615) increased $444$818 and IMNS ($2,614)1,880) increased $2,295,$1,054, while software revenue ($550)673) decreased $91,$6, compared towith the prior year quarter. Higher revenue in the firstsecond quarter of fiscal 2022 was largely due to the larger backlog at the start of the fiscal year compared towith the prior year amount. Software revenue was lower primarily due toessentially unchanged, reflecting lower professional services performed in the current quarter, offset by higher recurring software revenue. The receipt of orders is often uneven due to the timing of budget cycles, government financial issues and military conflict. As of DecemberMarch 31, 2021,2022, we had aggregate deferred revenue of $1,388$982 for extended warranty obligations and software support agreements.agreements

 

Gross Profit

The increase in gross profit compared towith the same period in the prior year was due to higher hardware revenue in this year’s quarter. Gross profit as a percentage of sales was essentially unchanged compared towith the prior year period primarily due to greater gross profit recognized on higherincreased hardware revenue and a more profitable revenue mix in this year’s quarter offset by higher costs from increased software related personnel added via acquisition and new hires in the last year to support the growing SasS product line.quarter.

 

As our products have varying gross margins, product mix may affect gross profits. In addition, our margins vary based on the sales channels through which our products are sold in a given period. We continue to implement product updates and changes, including raw material and component changes, that may impact product costs. We have limited warranty cost experience with product updates and changes and estimated future warranty costs can impact our gross margins. We do not believe that historical gross profit margins should be relied upon as an indicator of future gross profit margins.

 

29

Selling, General and Administrative Expenses

 

Selling, general and administrative expenses increased $1,803,$1,770, or 54.1%46.3%, over the prior year quarter. The increase was largely due to $982$701 of higher compensation expense from a 42%20% increase in sales and marketing personnel over the prior year, $379$443 increase in commission expense, $373 increased amortization expense, related to an acquisition, and $323$263 of higher travel, sales and marketing activities in the current year period.

 

We incurred non-cash share-based compensation expenses allocated to selling, general and administrative expenses in the three-months ended DecemberMarch 31, 2022 and 2021 of $686 and 2020 of $531 and $171,$309, respectively.

 

We may expend additional resources on the marketing and selling of our products in future periods as we identify ways to optimize potential opportunities. Commission expenses will fluctuate based on the nature of our sales.

 

Research and Development Expenses

 

Research and development expenses increased $303$1,016 this year as more engineering time was incurred to expand the base software offering, including expansion and integration of Zonehaven into the GEM software platform, as compared towith the prior year when more time was devoted to professional service contracts.

 

Included in research and development expenses for the three months ended DecemberMarch 31, 2022 and 2021, was $23 and 2020, was $12 and $6,$10, respectively, of non-cash share-based compensation costs.

 

Research and development costs vary period to period due to the timing of projects, and the timing and extent of using outside consulting, design and development firms. We seek to continually improve our product offerings, and we expect to continue to expand our product line with new products, customizations and enhancements. Based on current plans, we may expend additional resources on research and development in the current year compared to the prior year.

 

Net Loss

 

Net loss in the firstsecond quarter of fiscal year 2022 was $1,305, an increase$492, a decrease of $686,$754, compared towith the net lossincome of $262 in the firstsecond quarter of fiscal year 2021. The increasedecrease was primarily due to the increased operating expenses resulting from the acquisition of Zonehaven and additional engineering, sales and marketing employees.

29

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

Comparison of Results of Operations for the Six Months Ended March 31, 2022 and 2021 (in thousands)

  

Six Months Ended

         
  

March 31, 2022

  

March 31, 2021

         
      

% of

      

% of

         
      

Total

      

Total

  

Fav(Unfav)

 
  

Amount

  

Revenue

  

Amount

  

Revenue

  

Amount

  

%

 

Revenues:

                        

Product sales

 $21,424   89.8% $17,081   88.4% $4,343   25.4%

Contract and other

  2,421   10.2%  2,248   11.6%  173   7.7%

Total revenues

  23,845   100.0%  19,329   100.0%  4,516   23.4%
                         

Cost of revenues

  11,743   49.2%  10,350   53.5%  (1,393)  (13.5%)

Gross profit

  12,102   50.8%  8,979   46.5%  3,123   34.8%
                         

Operating expenses

                        

Selling, general and administrative

  10,631   44.6%  7,155   37.0%  (3,476)  (48.6%)

Research and development

  3,607   15.1%  1,964   10.2%  (1,643)  (83.7%)

Total operating expenses

  14,238   59.7%  9,119   47.2%  (5,119)  (56.1%)
                         

Loss from operations

  (2,136)  (9.0%)  (140)  (0.7%)  (1,996)  1425.7%
                         

Other income, net

  3   0.0%  61   0.3%  (58)  (95.1%)
                         

Loss before income taxes

  (2,133)  (8.9%)  (79)  (0.4%)  (2,054)  2600.0%

Income tax (benefit) expense

  (336)  (1.4%)  278   1.4%  614   220.9%

Net loss

 $(1,797)  (7.5%) $(357)  (1.8%) $(1,440)  403.4%
                         

Net revenue

                        

Hardware

 $22,622   94.9% $18,012   93.2%  4,610   25.6%

Software

  1,223   5.1%  1,317   6.8%  (94)  (7.1%)

Total net revenue

 $23,845   100.0% $19,329   100.0% $4,516   23.4%

Revenues

Revenues increased 23.4% for the six months ended March 31, 2022, compared with the same prior year period primarily due to the larger backlog as of September 30, 2021 compared with September 30, 2020. LRAD revenue was $18,127 for the current year six-month period, up $1,262, or 7.5%, IMNS revenue was $4,494, up $3,350, or 292.8%, and software revenue was $1,223, down $96 or 7.3% compared with the same prior year period. The receipt of orders will often be uneven due to the timing of approvals or budgets. As of March 31, 2022, we had aggregate deferred revenue of $982 for extended warranty obligations and software support agreements.

Gross Profit

The increase in gross profit in the six months ended March 31, 2022 was primarily due to higher sales volume. Gross profit as a percentage of revenue was higher compared to the prior year period primarily due to higher revenue and a better mix of revenue in the current year.

Our products have varying gross margins, so product mix may affect gross profits. In addition, our margins vary based on the sales channels through which our products are sold in a given period. We continue to implement product updates and changes, including raw material and component changes that may impact product costs. With such product updates and changes we have limited warranty cost experience and estimated future warranty costs can impact our gross margins. We do not believe that historical gross profit margins should be relied upon as an indicator of future gross profit margins.

30

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

Selling, General and Administrative Expenses

Selling, general and administrative expenses increased $3,476, or 48.6%, in the six months ended March 31, 2022 compared with the prior year period. The increase in selling, general and administrative expenses was largely due to a $1,727 increase in compensation related costs due to a 30% increase of sales and marketing personnel over the prior year, $374 increase in commission expense, $749 increase in amortization expense, and $586 in higher sales and marketing activities and travel.

We incurred non-cash share-based compensation expenses allocated to selling, general and administrative expenses in the six months ended March 31, 2022 and 2021 of $1,217 and $479, respectively.

We may expend additional resources on the marketing and selling of our products in future periods as we identify ways to optimize potential opportunities. Commission expenses will fluctuate based on the nature of our sales.

Research and Development Expenses

Research and development expenses increased $1,643, as more engineering time was incurred to expand the base software offering, including expansion and integration of Zonehaven into the GEM software platform.

We incurred non-cash share-based compensation expenses allocated to research and development in the six months ended March 31, 2022 and 2021 of $35 and $16, respectively.

Research and development costs vary period to period due to the timing of projects, amount of support provided on customer projects, and the timing and use of outside consulting, design, and development firms. We continually improve our product offerings, and we expect to continue to expand our product line with new products, customizations, and enhancements. Based on current plans, we may expend additional resources on research and development in the current year compared to the prior year.

Net Loss

Net loss of $1,797 for the first six months of fiscal 2022 increased $1,440 compared with a $357 net loss in the prior year period. This decrease was primarily due to the higher operating expenses, partially offset by the higher revenue and gross profit, in the current year period.

 

Other Metrics

 

We monitor a number of financial and operating metrics, including the following key metrics, to evaluate our business, measure our performance, identify trends affecting our business, formulate business plans and make strategic decisions. Our other business metrics may be calculated in a manner different than similar other business metrics used by other companies (in thousands):

 

Adjusted EBITDA

 

Adjusted EBITDA represents our net income before other income, net income tax expense (benefit), depreciation and amortization expense, and stock-based compensation. We do not consider these items to be indicative of our core operating performance. The items that are non-cash include depreciation and amortization expense and stock-based compensation. Adjusted EBITDA is a measure used by management to understand and evaluate our core operating performance and trends, and to generate future operating plans, make strategic decisions regarding allocation of capital, and invest in initiatives that are focused on cultivating new markets for our solutions. In particular, the exclusion of certain expenses in calculating adjusted EBITDA facilitates comparisons of our operating performance on a period-to-period basis. Adjusted EBITDA is not a measure calculated in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). We believe that adjusted EBITDA provides useful information to investors and others in understanding and evaluating our operating results in the same manner as our management and board of directors. Nevertheless, use of adjusted EBITDA has limitations as an analytical tool, and you should not consider it in isolation or as a substitute for analysis of our financial results as reported under U.S. GAAP. Some of these limitations are: (1) although depreciation and amortization are non-cash charges, the intangible assets that are amortized and property and equipment that is depreciated, will need to be replaced in the future, and adjusted EBITDA does not reflect cash capital expenditure requirements for such replacement or for new capital expenditure requirements; (2) adjusted EBITDA does not reflect changes in, or cash requirements for, our working capital needs; (3) adjusted EBITDA does not reflect the potentially dilutive impact of equity-based compensation; (4) adjusted EBITDA does not reflect tax payments or receipts that may represent a reduction or increase in cash available to us; and (5) other companies, including companies in our industry, may calculate adjusted EBITDA or similarly titled measures differently, which reduces the usefulness of the metric as a comparative measure. Because of these and other limitations, you should consider adjusted EBITDA alongside our other U.S. GAAP-based financial performance measures, net income and our other U.S. GAAP financial results.

 

3031

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

 

The following table presents a reconciliation of adjusted EBITDA to net income, the most directly comparable U.S. GAAP measure, for each of the periods indicated (in thousands):

 

 

Three months ended

 

Six months ended

 
 

Years ended September 30,

  

March 31,

 

March 31,

 
 

2021

  

2020

  

2022

  

2021

  

2022

  

2021

 

Net loss

 $(1,305) $(619) $(492) $262  (1,797) (357)

Other income, net

 (13) (69)

Income tax expense (benefit)

 (291) (5)

Other (income) expense, net

 10  8  (3) (61)

Income tax (benefit) expense

 (45) 283  (336) 278 

Depreciation and amortization

 639  281  643  270  1,282  552 

Stock-based compensation

  558   182   737   328   1,295   510 

Adjusted EBITDA

 $(412) $(230) $853  $1,151  $441  $922 

 

Liquidity and Capital Resources

 

Cash and cash equivalents as of DecemberMarch 31, 20212022 was $10,136,$8,977, down $3,031$4,190 compared with $13,167 atas of September 30, 2021. We had short-term marketable securities of $3,938$5,204 as of DecemberMarch 31, 2021,2022, compared with $5,686 atas of September 30, 2021. We had long-term marketable securities of $3,381 at December$2,264 as of March 31, 2021,2022, compared with $1,875 atas of September 30, 2021. In addition to cash and cash equivalents, short and long-term marketable securities, other working capital and expected future cash flows from operating activities in subsequent periods, we have a $10 million revolving line of credit available as a source of liquidity.

 

Although there is uncertainty related to the anticipated impact of the recent COVID-19 outbreak on the Company’s future results, we believe our efficient business model and strong balance sheet keep us positioned to manage our business through this crisis as it continues to unfold. We continue to manage all aspects of our business including, but not limited to, monitoring the financial health of our customers, suppliers and other third-party relationships and developing new opportunities for growth.

 

Principal factors that could affect our liquidity include:

 

 

ability to meet sales projections;

 

government spending levels;

 

introduction of competing technologies;

 

product mix and effect on margins;

 

ability to reduce current inventory levels;

 

product acceptance in new markets;

 

value of shares repurchased;

 

value of dividends declared;

supply chain disruption;

inflation;

conflict between Russia and Ukraine;

 

impact of COVID-19 on global market conditions; and

 

impact of COVID-19 on customers’ ability to pay.

 

Principal factors that could affect our ability to obtain cash from external sources include:

 

 

volatility in the capital markets; and

 

market price and trading volume of our common stock.

 

Based on our current cash position, and assuming currently planned expenditures and level of operations, we believe we have sufficient capital to fund operations for the twelve-month period subsequent to the issuance of the interim financial information. However, we operate in a rapidly evolving and unpredictable business environment that may change the timing or amount of expected future cash receipts and expenditures. Accordingly, there can be no assurance that we may not be required to raise additional funds through the sale of equity or debt securities or from credit facilities. Additional capital, if needed, may not be available on satisfactory terms, or at all.

 

3132

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

 

Cash Flows

 

Our cash flows from operating, investing and financing activities, as reflected in the condensed consolidated statements of cash flows, are summarized in the table below:

 

 

Three months ended

  

Six months ended

 
 

December 31, 2021

  

December 31, 2020

  

March 31, 2022

  

March 31, 2021

 

Cash provided by (used in):

      

Operating activities

 $(2,702) $1,272  $(3,107) $363 

Investing activities

 $72  $(4,264) (146) (4,375)

Financing activities

 $(395) $54  (915) (27)

 

Operating Activities

 

Net loss of $1,305$1,797 for the threesix months ended DecemberMarch 31, 20212022 was decreased by $1,131$2,715 of non-cash items that included share-based compensation, depreciation and amortization, amortization of operating lease ROU assets, an increase to deferred income taxes, share-based compensation, depreciation and amortization, warranty provision and inventory obsolescence. Cash used by operating activities in the quartercurrent year reflected an increase in inventory of $2,752$3,291, and a decrease in accrued liabilities and other of $1,743 for$4,412 reflecting a decrease in the balances of customer deposits received, and payment of incentive compensation earned in fiscal year 2021. This was offset by an $889a $2,123 decrease in accounts receivable on lower revenue this quarter compared to the fourth quarter of fiscal year 2021, a $979$750 decrease in prepaid expenses and a $99$805 increase in accounts payable.

 

Net loss of $619$357 for the threesix months ended DecemberMarch 31, 20202021 was increasedoffset by $667$1,864 of net non-cash items that included depreciation and amortization, share-based compensation, operating lease ROU asset amortization, warranty provision, inventory obsolescence, and both realized and unrealized loss on a foreign currency forward contract.contract and a reduction to deferred income taxes. Cash used byin operating activities infor the quartercurrent year reflected an increase in inventory of $1,114 due to a fiscal first quarter customer order that was not shipped until the fiscal second quarter, and a net decrease of $314 in accrued and other liabilities of $1,363, primarily for paymenta $514 decrease in customer deposits resulting from shipments for the year to date and $491 of incentive compensation earnednet lower accrued payroll and related liabilities, an increase of $698 in fiscal year 2020, offset by increased customer deposits.inventory to support the current backlog, a $253 increase in prepaid expenses and an increase in accounts receivable of $14. Cash provided by operating activities included a decrease in accounts receivable of $2,300 due to lower fiscal first quarter revenue compared to shipments in the fourth quarter of fiscal year 2020, lower prepaid expenses and other of $120, and an increase in accounts payable of $232.$1,184, primarily for inventory related purchases.

 

We had accounts receivable of $6,787$5,550 as of DecemberMarch 31, 2021,2022, compared with $7,682 as of September 30, 2021. Terms with individual customers vary greatly. We regularly provide thirty-day terms to our customers if credit is approved. Our receivables can vary dramatically due to overall sales volume, quarterly variations in sales, timing of shipments to and receipts from large customers, payment terms, and the timing of contract payments.

 

As of DecemberMarch 31, 20212022 and September 30, 2021, our working capital was $15,433$16,839 and $18,019, respectively. The decrease in working capital was primarily due to the net loss this quarter,year, change in the short-term/long-term mix of marketable securities, and the use of cash to repurchase shares of Company stock.

 

Investing Activities

 

Our net cash provided by investing activities was $72 for the three months ended December 31, 2021, compared with cash used in investing activities of $4,264was $146 for the threesix months ended DecemberMarch 31, 2020.2022, compared with $4,375 for the six months ended March 31, 2021. In the first quartersix months of fiscal 2021, $4,367 was used for the Amika Mobile asset purchase. In the first quartersix months of fiscal 2022, we decreased our holdings of short and long-term marketable securities by $231,$25, compared with a decrease of $132$140 in the threesix months ended DecemberMarch 31, 2020.2021. Cash used in investing activities for the purchase of property and equipment was $159$171 and $29$148 for the threesix months ended DecemberMarch 31, 20212022 and 2020,2021, respectively. We anticipate some additional expenditures for tooling and equipment during the balance of fiscal year 2022.

 

Financing Activities

 

In the threesix months ended DecemberMarch 31, 2021, proceeds2022, we used $915 compared with $27 for financing activities for the six months ended March 31, 2021. In the first six months of fiscal 2022 we received $170 from the exercise of stock options provided $46and used $998 to repurchase shares of our common stock and $70 to settle statutory tax withholding requirements upon vesting of restricted stock units. In the first six months of fiscal year 2021 we received $170 from the exercise of stock options, which was offset by $141 of cash compared with proceeds fromused to settle statutory tax withholding requirements upon vesting of restricted stock options of $54 for the three months ended December 31, 2020.awards.

 

In December 2018, the Board of Directors approved a new share buyback program beginning January 1, 2019, under which the Company was authorized to repurchase up to $5 million of its outstanding common shares. In December 2020, the board voted to extend this program’s expiration date to December 31, 2022. During the quartersix months ended DecemberMarch 31, 2021, 116,8682022, 259,310 shares were purchased for $441.$998. No shares were repurchased during the quartersix months ended DecemberMarch 31, 2020.2021. All repurchased shares have been retired and as of DecemberMarch 31, 2021, $3.72022, $3.0 million was available for share repurchase under this program.

 

3233

Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

 

Recent Accounting Pronouncements

 

New pronouncements issued for future implementation are discussed in Note 3, Recent Accounting Pronouncements, to our condensed consolidated financial statements.

 

Item

Item 3.Quantitative and Qualitative Disclosures about Market Risk.

Quantitative and Qualitative Disclosures about Market Risk.

 

Foreign Currency Risk

 

We consider our direct exposure to foreign exchange rate fluctuations to be minimal. The transactions of our Spanish subsidiary are denominated primarily in Euros and the transactions of our Canadian subsidiary are denominated primarily in Canadian dollars, which is a natural hedge against foreign currency fluctuations. All other sales to customers and all arrangements with third-party manufacturers, with one exception, provide for pricing and payment in U.S. dollars, and, therefore, are not subject to exchange rate fluctuations. Increases in the value of the U.S. dollar relative to other currencies could make our products more expensive, which could negatively impact our ability to compete. Conversely, decreases in the value of the U.S. dollar relative to other currencies could result in our suppliers raising their prices to continue doing business with us. Fluctuations in currency exchange rates could affect our business in the future.

 

Item

Item 4.Controls and Procedures.

Controls and Procedures.

 

We are required to maintain disclosure controls and procedures designed to ensure that material information related to us, including our consolidated subsidiaries, is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms.

 

Conclusion Regarding the Effectiveness of Disclosure Controls and Procedures

 

Under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, we conducted an evaluation of our disclosure controls and procedures as such term is defined under Rules 13a-15(e) and 15d-15(e) promulgated under the Securities Exchange Act of 1934. Based on this evaluation, our principal executive officer and our principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of DecemberMarch 31, 2021.2022.

 

Changes in Internal Control over Financial Reporting

 

There have been no changes in our internal control over financial reporting during our fiscal quarter ended DecemberMarch 31, 2021,2022, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. Our process for evaluating controls and procedures is continuous and encompasses constant improvement of the design and effectiveness of established controls and procedures and the remediation of any deficiencies, which may be identified during this process.

 

Because of the inherent limitations of internal control over financial reporting, including the possibility of collusion or improper management override of controls, material misstatements due to error or fraud may not be prevented or detected on a timely basis. Also, projections of any evaluation of the effectiveness of the internal control over financial reporting to future periods are subject to the risk that the controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

 

PART II. OTHER INFORMATION

Item 1.Legal Proceedings.

Legal Proceedings.

 

We may at times be involved in litigation in the ordinary course of business. We will also, from time to time, when appropriate in management’s estimation, record adequate reserves in our consolidated financial statements for pending litigation. Currently, there are no pending material legal proceedings to which the Company is a party or to which any of its property is subject.

 

Item 1A.

Risk Factors.

There have been no material changes to the risk factors described under Item1A.Risk Factors. 1A of our Annual Report on Form 10-K for the fiscal year ended September 30, 2021, filed with the SEC on November 23, 2021, except for those noted below:

 

The conflict between Russia and Ukraine and the related implications may negatively impact our operations.


          In February 2022, Russia invaded Ukraine.
As a Smaller Reporting Companyresult, the U.S. and certain other countries have imposed sanctions on Russia and could impose further sanctions, as definedwell as potential retaliatory actions by Rule 12b-2Russia, that could damage or disrupt international commerce and the global economy. It is not possible to predict the broader or longer-term consequences of this conflict or the impact of sanctions, embargoes, regional instability, geopolitical shifts and adverse effects on macroeconomic conditions, security conditions, currency exchange rates and financial markets. Such geopolitical instability and uncertainty could have a negative impact on our ability to sell, ship products, collect payments, and support customers in certain regions based on trade restrictions, embargoes and export control law restrictions, supply disruptions, and logistics restrictions including closures of air space, and could increase the costs, risks and adverse impacts from supply chain and logistics challenges.

The potential effects of the Exchange Actconflict between Russia and Ukraine also could impact many of the other risk factors described in item 10(f)(1)Item 1A, Risk Factors, in our Annual Report on Form 10-K for the fiscal year ended September 30, 2021. Given the evolving nature of Regulation S-K,this conflict, the related sanctions, potential governmental actions and economic impact, such potential impacts remain uncertain. While we expect the impacts of conflict between Russia and Ukraine could have an effect on our business, financial condition and results of operations, we are electing scaled disclosure reporting obligations and therefore are not requiredunable to providepredict the information requested byextent or nature of these impacts at this item.time.

 

3334

 

Item2.Unregistered Sales of Equity SecuritiesGenasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and Use of Proceeds.share amounts)

(Unaudited)

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds.

 

In December 2018, the Board of Directors approved a share buyback program beginning January 1, 2019 and expiring on December 31, 2020, under which the Company was authorized to repurchase up to $5 million of its outstanding common shares. In December 2020, the Board of Directors extended the buyback program until December 31, 2022.

 

The following table discloses the stock repurchases during the quarter ended DecemberMarch 31, 2021.2022.

 

 

Period

 

Total Number of

Shares

Purchased

  

Average Price

Paid per Share

  

Maximum dollar value of

shares that may be purchased

under the program

 

October 1, 2021 - October 31, 2021

  -  $-  $4,051,745 

November 1, 2021 - November 30, 2021

  -  $-  $4,051,745 

December 1, 2021 - December 31, 2021

  116,868  $3.77  $3,610,833 
   116,868         

Period

 

Total Number of

Shares

Purchased

  

Average Price

Paid per Share

  

Maximum dollar value of

shares that may be purchased

under the program

 

January 1, 2022 - January 31, 2022

  142,442  $3.91  $3,053,761 

February 1, 2022 - February 28, 2022

  -  $-  $3,053,761 

March 1, 2022 - March 31, 2022

  -  $-  $3,053,761 
   142,442         

 

Item

Item 3.Defaults Upon Senior Securities.

Defaults Upon Senior Securities.

 

None.

 

Item

Item 4.Mine Safety Disclosures.

Mine Safety Disclosures.

 

Not Applicable.

 

Item

Item 5.Other Information.

Other Information.

 

On February 4, 2022, the Company's Board of Directors adopted the Genasys Inc. Change in Control Severance Benefit Plan (the "Change in Control Plan"), which provides certain severance and other benefits to participating officers whose employment is terminated in connection with or following a change of control of the Company. The Change in Control Plan supersedes and replaces any prior plans, policies and practices applicable to the participating executives relating to severance or vesting acceleration upon a change of control of the Company. Dennis D. Klahn, Chief Financial Officer, and Norman Carmichael, Vice President of Operations, are currently the only participating officers in the Change of Control Plan.

The Change of Control Plan provides that in the event of a qualifying termination, each of the participating executives will be entitled to receive (i) a lump sum payment equal to twenty-four months' of the participating officer's base salary (less applicable tax and other withholdings), (ii) a lump sum payment equal to the participating officer's target bonus for the year in which the officer is terminated, (iii) continuation of health benefits for twenty-four months and (iv) accelerated vesting of any unvested stock options and other securities or similar incentives held by the participating officer at the time of termination. A qualifying termination under the Change of Control Plan is any involuntary termination without cause or any voluntary termination for good reason, in each case occurring within three months before or twelve months after a change of control of the Company.

Item6.Exhibits. None.

 

10.1

Item 6.

Change in Control Severance Benefit Plan, adopted February 4, 2022+*

Exhibits.

31.1

Certification of Richard S. Danforth, Principal Executive Officer, pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

  

31.2

Certification of Dennis D. Klahn, Principal Financial Officer, pursuant to Rule 13a-14(a) or 15d-14(a) of the Securities and Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.*

  

32.1

Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, executed by Richard S. Danforth, Principal Executive Officer and Dennis D. Klahn, Principal Financial Officer.*

  

101.INS

Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)Document*

  

101.SCH

Inline XBRL Taxonomy Extension Schema Document*

  

101.CAL

Inline XBRL Taxonomy Extension Calculation Linkbase Document*

  

101.DEF

Inline XBRL Taxonomy Extension Definition Linkbase Document*

  

101.LAB

Inline XBRL Taxonomy Extension Label Linkbase Document*

  

101.PRE

Inline  XBRL Taxonomy Extension Presentation Linkbase Document*

  
104Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)

 


*         Filed concurrently herewith.

+         Management contract or compensatory plan or arrangement. 

Filed concurrently herewith.

 


Genasys Inc.

Notes to the Condensed Consolidated Financial Statements

(in thousands, except per share and share amounts)

(Unaudited)

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

 

GENASYS INC.

   

Date: February 7,May 9, 2022

By: 

/s/    Dennis D. Klahn

  

Dennis D. Klahn, Chief Financial Officer

  

(Principal Financial Officer)

 

3536